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CHAPTER I 
 
REVIEW OF LITERATURE 
 
Immune System at a glance 
 
Our body is invaded by myriads of organisms on a daily basis. In order to combat 
these invaders, an extremely complex and sophisticated network of cells and mechanisms 
collectively termed as the immune system is in place. The immune system is divided into 
two main branches: innate immunity and acquired immunity. Innate immunity entails the 
defense mechanisms that an individual is born with and acquired immunity is the 
immunity that an individual obtains during the course of his/ her development. When the 
body encounters a pathogen, the first line of defense is mounted by the innate immune 
system to eliminate the invading organism/source. When the innate immune system fails, 
the acquired immune system is triggered to purge the invasion. Some of the major cells 
that are a part of the immune system include T and B lymphocytes, neutrophils, basophils 
, macrophages, monocytes, eosinophils and dendritic cells.  
Hematopoiesis  involves the development of immune system cells, platelets and 
erythrocytes from primitive stem cells and this process usually occurs in the bone marrow 
(1). Almost all of the immune system cells arise from a common hematopoietic stem cell 
or HSC. This stem cell divides to generate a progenitor cell from which different cell 
types originate. The cells of the immune system are derived mainly from one of the two 
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main lineages: the lymphoid lineage and the myeloid lineage. The third lineage is the 
erythroid lineage which is a source of erythrocytes and platelets. The lymphoid lineage 
serves as a source of lymphocytes and natural killer cells which are the main players of 
adaptive/acquired immunity whereas the myeloid lineage yield inflammatory cells and 
cells of the innate immunity branch.  
Progenitor and precursor cell differentiation is governed by the presence or 
absence of a variety of cytokines released by bone marrow stromal cells. Hematopoietins 
are the major class of cytokines that drive the differentiation of blood cells in the bone 
marrow. Some of the other cytokines that play a significant role in directing the 
differentiation include colony stimulating factors and interleukins. The differentiation of 
some of the cells is completed in the bone marrow. However some cells have to pass 
through additional stages to complete maturation. They might leave the bone marrow as 
immature cells and complete their process of maturation at distant sites or locations. 
Dendritic Cells 
Dendritic cells, often called as ontogenic orphans, are professional antigen 
presenting cells (APC) that are rare but ubiquitous.  Identified by Steinman and 
colleagues in 1972,these cells are the sentinel cells of the immune system(2). Professional 
antigen presenting cells capture antigens, process them and present them to the 
lymphocytes which in turn activate the lymphocytes. They arise from hematopoietic stem 
cells and exhibit characteristic dendritic morphology and strong antigen-presenting 
capacity (1). They do not exhibit lineage-specific markers like CD3,CD19,CD16 and 
CD14 which are expressed respectively by T cells, B cells, NK cells and monocytes (1). 
DC can follow either one of the two developmental lineages; lymphoid or myeloid. They 
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differ in their function and surface marker expression. Lymphoid DC express the marker 
CD8α which is absent in myeloid DC. Lymphoid DC are mainly involved in immune 
tolerance and myeloid DC capture antigens in the periphery, migrate to secondary 
lymphoid organs and activate specific T cells (3-4). 
Dendritic cells are extremely versatile cells of the innate immune system with 
distinct functions and exhibit several distinct forms. They are distributed in a variety of 
tissues and organs including non lymphoid tissues like skin, mucosa, organs like the heart 
and the kidneys, as well as peripheral blood and lymph. The prime location of dendritic 
cells is the T cell dependent areas of lymphoid tissue (5). Dendritic cells residing in the 
epidermis are called Langerhans cells while the dendritic cells populating the T cell rich 
region of secondary lymphoid organs are called interdigitating dendritic cells (6). The 
other locations include the thymic medulla and B cell follicles of secondary lymphoid 
organs. DC residing in the dermis are known as dermal dendritic cells or interstitial 
dendritic cells. There is also a very distinct group of cells that are characterized as 
dendritic cells but cannot present antigens efficiently to naïve T cells (7). These are called 
the plasmacytoid dendritic cells. They play an important role in mounting adaptive 
responses to viral infection. They have a larger repertoire of IFNA genes compared to 
other dendritic cells and secrete enormous amounts of IFN-α in response to a variety of 
viral and non viral stimuli (8). Plasmacytoid DC lack cd11c or express very low cd11c, 
express TLR9 and TLR7 and are involved in the development of regulatory T cells and 
tolerance (8-9). 
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Developmental Cycle of Dendritic Cells 
Dendritic cells also originate from the bone marrow during hematopoiesis (2). 
There are distinct hematopoietic lineages of DC. This includes lymphoid related DC, 
monocyte derived DC and myeloid DC. A common lymphoid progenitor cell is the 
ancestor of lymphoid related DC. These cells are inept at differentiating into monocytes. 
Monocyte-derived DCs are generated by monocytes. This transition is mainly caused by 
GM-CSF and IL-4 (1).The phenotype of these cells is transient. Myeloid DC arise from 
clonogenic precursors distinct from the precursors of myeloid cells. These cells develop 
independently and distinctly from monocytes (1). Dendritic cell precursors leave the bone 
marrow to populate different organs and tissues. 
Dendritic cells usually reside as immature cells at different tissues and interstitial 
spaces. They mature when exposed to a variety of stimuli. Mature and immature dendritic 
cells exhibit characteristic differences in terms of cell surface expression and functions. 
Immature dendritic cells have high amounts of intracellular MHCII proteins but they are 
retained within the cell with very little surface expression (10). They are extremely 
efficient in taking up antigens and cellular debris via receptor mediated endocytosis, 
phagocytosis or micropinocytosis. In the immature form DC express CD1a and have very 
low capacity for T cell stimulation. They lack adhesive and co stimulatory molecules like 
CD40/80/86 required for activation of T cells. They also have low levels of CD25,DEC-
205(10-11).However, they express receptors for inflammatory cytokines like CCR1. 
Immature DC constantly scans their surrounding milieu for invading organisms or 
foreign particles. 
 A maturation signal is usually received from local infection. Upon matura
dendritic cells change their morphology. They exhibit dendrites or have a veiled 
appearance. They upregulate receptors that are required for migration, such as the CCR7 
receptor. MHC I and II are expressed at high levels on the surface. They lose the
phagocytic ability and acquire co stimulatory molecules like CD80/86/40 that are 
required for activating T cells 
were residing in and migrate to secondary lymphoid organs where they present the 
captured antigens to the resident T cells. Maturation of dendritic cells is a constant 
process which is not dictated by the presence of infection. Dendritic cells can mature in 
the absence of infection and these cells do not mediate effector differentiation of naïve T 
cells. 
Figure 
5 
(10). These cells then leave the tissue/organ where they 
1: Developmental Cycle of Dendritic Cells 
tion, 
ir 
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Immune regulation of dendritic cells is mostly via programmed cell death or apoptosis 
which is an extremely regulated and controlled event. DC undergo apoptosis if they fail 
to receive signals from the T cells (3). Apoptosis is a part of the developmental cycle of 
DC. DC can undergo apoptosis during three different phases of their development. These 
include the initial progenitor stages where the progenitors that failed to undergo further 
development underwent apoptosis, intermediate stages during precursor selection and 
finally at the mature level after activating T cells or in the absence of appropriate signals 
(10). 
Functions of Dendritic Cells 
 
DC are the guard cells of the immune system. They constantly scrutinize their 
environment for antigens. Even under homeostatic conditions, there is a small rate of DC 
turn over. Even in the absence of inflammation or antigen stimulation, DC migrate from 
the peripheral tissues to secondary lymphoid organs (12-13).  
Antigen acquisition 
 
As antigen presenting cells, DC are required to capture antigens,  process them 
and present the processed peptides to T cells (14). Dendritic cells capture antigens by a 
variety of methods. They can internalize antigens by means of receptor mediated 
endocytosis or phagocytosis (15).When receptor mediated uptake  fails, DC can still 
internalize antigens via pinocytosis which involves micropinocytosis and 
macropinocytosis (16). Almost all cells are capable of micropinocytosis however 
macropinocytosis is a special function possessed by only a few cells. Dendritic cells can 
efficiently take up macrosolutes via macropinocytosis and concentrate them in MHC 
loaded compartments (16). 
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Antigen Processing 
 
MHC molecules are a group of proteins that are encoded in the major 
histocompatibility complex .These proteins play important roles in governing the immune 
responses. These proteins bind to peptide fragments of proteins internalized by the cell 
and display the degraded peptide on the surface for T cell recognition and activation. 
Naive T cells can be activated only if the peptides are presented in context with an MHC 
molecule (17). There are two major classes of MHC molecules; MHC Class I and MHC 
Class II. They differ both structurally and also with respect to the peptides they bind to. 
CD4T cells can recognize antigens when they are in context with MHCII whereas CD8T 
cells can recognize only MHC class I associated peptides. 
Within a cell there are two main areas that need to be surveyed for infection. This 
includes the cytosol which is the potential site for viral replication and intracellular 
bacteria and endosomal/lysosomal compartments that harbor the antigens derived from 
internalized extracellular pathogens and bacteria.MHC class I molecules bind to the 
peptides derived from the cytosolic compartment whereas MHC class II is associated 
with sampling the endosomal/lysosomal compartment (11). MHC class I molecules are 
expressed by almost all the body cells with an exception of erythrocytes. However, 
expression of MHC class II molecules is restricted to only specialized cells like antigen 
presenting cells and phagocytic cells. Dendritic cells are capable of processing antigens 
and presenting them in context of MHCI and MHC II indicating their ability to prime 
both CD4+ and CD8+ T cells (18). 
The peptides derived from endogenous antigens degraded by the proteosome 
complex in the cytosol are transported to the endoplasmic reticulum where they are 
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loaded onto MHC class I proteins. The assembly then proceeds to the cell surface for 
display. The MHC class II processing takes place initially in the endoplasmic reticulum 
where the MHCII molecules assemble. They are then chaperoned to the 
endosomal/lysosomal pathway wherein they bind the peptides derived from exogenous 
antigens. The entire complex is transported to the surface for expression (11, 19). 
 Dendritic cells are highly efficient in antigen processing and presentation. They 
are capable of forming MHC-peptide complexes from internalized cells. In the absence of 
a signal the MHC II expression on immature DC is kept minimal. Upon antigen 
stimulation, the peptide loaded MHC II that reach the surface remains on the surface with 
the shutting down of further MHC II production (11).These peptides are then presented to 
T cells. 
 Dendritic cells can effectively process exogenous antigens and load them in MHC 
class II complex for presentation. 
Antigen Presentation 
 
Dendritic cells are called professional antigen presenting cells since they are the 
only cells that can activate naïve T cells. The processed peptides with the MHC complex 
are displayed for T cell receptor binding. The T cell receptor must bind to the peptide-
MHC complex with high affinity so that the T cell receptor signal is prolonged enough to 
initiate further events downstream. This requires involvement of co receptors and co 
stimulatory molecules present on both T cells and dendritic cells. Some of the co 
stimulatory molecules include CD80 and CD86 on the dendritic cells. 
 Mature dendritic cells are also capable of cross presentation wherein the peptides 
derived from the endosomal compartments are loaded in to MHCI molecules as well. 
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Thus dendritic cells can activate both CD8 and CD4 T cells against peptides derived from 
the same antigen/organism. 
Dendritic cells also play a role in the induction of tolerance. Dendritic cells can 
process antigens derived from apoptotic cells and present them in context with MHC 
class molecules. This would either stimulate or tolerize CD8 positive cytotoxic  
lymphocytes (20-21). Tolerance can be induced only via apoptosis since necrosis can 
bring about a stimulatory response (20). There is a reasonable argument that migratory 
immature dendritic cells respond to apoptotic cell death in the peripheries. After 
capturing the apoptotic bodies, these immature DC migrate to the lymph nodes wherein 
they present the captured antigens to DC housed in the lymph nodes (22). The resident 
DC processes the short-lived migratory DC and induces tolerance. These DC are 
sometimes referred to as regulatory/tolerogenic DC and exhibit high MHC-peptide 
complexes and low CD86. They cannot drive T cells through a stimulatory pathway. DC 
are required for negative selection and not for positive selection (22).It is proposed that 
peripheral tolerance mediated by migratory DC complements central tolerance. 
Peripheral tolerance seems to be essential to prevent autoimmune responses against 
harmless environmental and tissue antigens that do not gain access to the negative 
selection process in the thymus. When low doses of soluble antigens are encountered by 
DC in the steady state they induce peripheral tolerance to these antigens (22). T cells that 
interact with tolerogenic DC get deleted after few rounds of division. Tolerogenic DC 
exhibit low levels of co stimulatory molecules, low allostimulatory activity , low CCR7 
expression and release IL-10 which is an immune suppressive cytokine (9). 
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Migration  
 
Even though migration cannot be considered as a function it is a very important 
aspect of DC development. Dendritic cells migrate from the tissues where they reside in 
or peripheral blood to various lymphoid organs (23). One of the major routes of DC 
migration is from the peripheral tissues to the draining lymph nodes (24). Migration of 
dendritic cells is a very critical process and is tightly regulated. DC migration is critical 
owing to the fact that T cells are usually found in the T cell rich regions of secondary 
lymphoid organs. DC have to reach T cell regions in order to deliver the signals and 
activate the T cells to mount an immune response. 
Chemokine and Cytokine Secretion. 
 
Cytokines are low-molecular-weight proteins released by immune system cells 
and other cells of the body. Cytokines play important roles in the development and 
effector functions of immune system cells. Unlike hormones, cytokines exert their effects 
locally over short distances. They are intercellular messengers that relay information that 
are vital for the functioning of the immune system and could bring about proliferation, 
activation, differentiation, immunoglobulin class switching or block all of the above in 
target cells (25). Chemokines are cytokines that are chemotactic. They are small proteins 
and are characterized by the presence of four cysteine residues in conserved regions.  
Dendritic cells are capable of releasing cytokines and chemokines. The array of 
cytokines secreted by dendritic cells depends upon the stage of the cell. Apart from 
secreting cytokines, DC also express cytokine receptors which would enable them to 
respond to the cytokines that act in an autocrine or paracrine fashion. When stimulated 
with phytohemagglutinin, DC release a wide array of cytokines of which IL-9 and Rantes 
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are important owing to the fact that they are not released by monocytes (26). 
Unstimulated DC also exhibit cytokine transcripts although it is not as pronounced as it is 
in an activated DC. DC are capable of producing multiple cytokines that have multiple 
functions (27).Of importance is IL-12 which plays a significant role in the development 
of Th1 cells. DC can produce IL-12 and thus influence the switch between Th1 and Th2 
cells (28). 
 
Dendritic Cells and Tumors 
 
 Most tumors are poorly immunogenic and thus fail to elicit an immune response. 
As discussed earlier, DC have strong antigen presenting capacity and are important for 
activating T lymphocytes. DC are capable of stimulating tumor specific T cells. It has 
been reported that Langerhans cells can effectively present tumor associated antigens and 
stimulate CD4+ T cells (29-30). Bone-marrow derived DC can induce both cytolytic and 
proliferative anti tumor responses from naïve splenocytes. Naïve T cells incubated with 
tumor lysate-pulsed DC gave a proliferative response (31). These cells could also 
effectively lyse the tumor cells (31). Apart from stimulating tumor specific T 
lymphocytes, DC can also be effective for tumor immunization. Immunization of mice 
with tumor lysates-pulsed DC protected the animal from subsequent tumor challenge (31-
32). Also, tumor lysates-pulsed DC could reduce the establishment of distant metastatic 
foci by 90% (31). 
 Owing to the fact that dendritic cells can initiate anti-tumor responses, it is not 
surprising to find that tumor cells elaborate mechanisms to alter DC functions in order to 
benefit their survival. This alteration could be manifested as a block in the DC 
infiltration, complete abrogation of phagocytosis, inhibition of DC maturation and /or 
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obstruction of DC migration into the lymph nodes (33). Gabrilovich et.al showed that 
tumor cells altered DC differentiation from progenitor cells to suit their survival (34). 
Bone marrow derived dendritic cells (BMDC) in the presence of viable or irradiated 
tumor cells exhibited an increase in the cell surface molecule expression (35). Markers 
like CD80, B7-DC, which would aid in tumor survival, were expressed at higher levels. 
However, this expression was not as high as compared to that induced by LPS and Poly-
IC. Tumor cells interfered with the ability of BMDC to respond to TLR stimuli.  Tumor 
cells partially impaired the up regulation of co stimulatory molecules by LPS and Poly-
IC. It is interesting to note that the expression of CD80 and B7-DC were not affected by 
tumor cells. When incubated with tumor cells these cells failed to produce cytokines even 
in the presence of TLR agonists like LPS and Poly-IC. Even though irradiated /viable 
tumor cells could enable co stimulatory expression on BMDC,BMDC failed to produce 
cytokines necessary for the complete activation of T cells (35). Curiel et.al showed that 
DC from ovarian cancer tissue expressed B7-H1, a negative regulator of cytotoxic T 
cells, constitutively thereby affecting their ability to activate T cells (36). 
 Various tumor tissues such as breast, stomach, lung, bladder are infiltrated with 
dendritc cells (33). Bell et.al. demonstrated that tumor infiltrating dendritic cells [TIDC] 
have an immature phenotype compared to the DC in the surrounding tissue  and mature 
CD83+ DC were restricted to the peritumoral regions (37). It was speculated that the 
increased number of TIDC are due to the chemotactic factors released by the tumor cells. 
Gabrilovich et.al reported that DC isolated from tumor tissue exhibited diminished 
capacity to stimulate allogenic T cells and it was speculated that the low MHC class II 
expression on these cells could be responsible for the impaired APC function.  However, 
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the suppressed phenotype of TIDC could be reverted with the administration of CpG 
nucleotides and anti IL-10 receptor antibody in vivo and in vitro or by overnight ex vivo 
culture (38-39) . Similar findings corresponding to TIDC were obtained for circulating 
DC from tumor patients (40-42). To sum up, TIDC and circulating DC from cancer 
patients or tumor bearing animals have compromised functions. Having outlined the role 
played by DC in a tumor milieu, the next section focuses on the main candidate of this 
research topic namely Endothelial Monocyte Activating Polypeptide II (EMAPII). 
 
EMAPII 
  
EMAPII is a product released during apoptosis and since it is also a product of 
tumor cells, it may alter tumor directed immune responses. The section outlines the 
discovery of this protein, followed by its sequencing and in-depth study of the myriads of 
functions performed by this protein. The discussion then focuses on the therapeutic 
potentials of EMAPII. 
In order to escape immunosurveillance, tumors elaborate a variety of 
procoagulants which could aid in fibrin deposition and coagulation (43). Even though, 
this could abet the tumor to mask itself from the host defenses, extensive intravascular 
coagulation could obstruct the blood flow to the tumor. This would divest the tumor from 
obtaining essential nutrients. Various cytokines and factors can bring about thrombus 
formation and intravascular coagulation. Tumor necrosis factor can bring about 
procoagulant activity in human vascular endothelium (44).  
Tumor necrosis factor (TNF), a cytokine primarily released by macrophages, is a 
key player in apoptosis, inflammation, cell survival and immunity. Induced by 
endotoxins,  this multifunctional cytokine causes necrosis of Meth A sarcomas and other 
14 
 
tumors (45-46).With the support from additional data, the European Agency for the 
Evaluation of Medicinal Products (EMEA) approved the clinical use of this cytokine to 
treat soft tissue sarcoma via limb perfusion approach (47). TNF is currently administered 
in tumor therapy for soft tissue sarcomas, metastatic melanomas and a variety of other 
tumors (46). 
When TNF was infused into methylcholantherene A induced fibrosarcomas, it 
caused extensive coagulation in the tumor vasculature and obstructed the blood flow to 
the tumor bed (48). It was hypothesized that tumor cells elaborate factors that prime the 
response of endothelial cells to TNF. It was observed that methA fibrosarcoma derived 
tumor supernatant could induce tissue factor in endothelium in response to sub maximal 
concentrations of TNF(48).  
The focus then shifted to isolating tumor derived factors that enhanced tissue 
factor expression in endothelial cells. This led to the isolation of a 44KD polypeptide 
from methA derived fibrosarcoma tumor supernatant. This polypeptide was purified and 
characterized for its effect on endothelial cells in the presence of TNF. It augmented the 
tissue factor induction on endothelial cells in response to varying concentrations of 
TNF(49). This polypeptide was named Endothelial and Monocyte Activating Polypeptide 
I. Another polypeptide was also isolated from methA fibrosarcoma tumor supernatant 
based on its ability to alter endothelial and monocyte functions. This 22KD polypeptide 
was called Endothelial monocyte activating polypeptide II (EMAPII)(50). Its unique 
amino terminal sequence was used to raise antibodies in rabbits and this sequence 
showed homology to human vonWillebrand antigen II. Purified EMPAII induced 
procoagulant activity in endothelial cells in a dose dependent manner. The level of tissue 
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factor mRNA transcripts increased with increasing concentrations of EMAPII suggesting 
a biosynthetic role. EMAPII was also sensitive to reduction and trypsin treatment. It 
could also induce procoagulant activity in monocytes which occurred in a time dependent 
manner and was inhibited in the presence of trypsin. Injection of EMAPII into mouse 
footpads resulted in an acute inflammatory response characterized by edema and 
infiltration of mononuclear cells (50). 
Structure of EMAPII 
 
EMAPII cDNA was cloned using a portion of the unique NH2 terminal sequence 
to generate degenerate primers (51-52).Human EMAPII cDNA shared 86% identity with 
murine EMAPII cDNA with the human sequence containing two additional amino acids. 
It was observed that the mature EMAPII NH2-terminal sequence was encoded by an 
internal sequence which led to the hypothesis that EMAPII is generated from a 
preproprotein; a larger polypeptide. However, hydropathy analysis did not reveal any 
secreted hydrophobic signal peptide for this protein. This was similar to interleukin 1β 
that also lacked a classic signal peptide but was released as pre-IL1β, which was later 
proteolytically cleaved to release mature IL1β.  An Asp residue in the P-1 position was 
necessary for this cleavage and EMAPII protein also had Asp residue in the P-1 position. 
It was therefore speculated that a cysteine protease similar to the one acting ILβ 
conversion is responsible for releasing mature EMAPII from its pro-form. A tetra 
peptide-based inhibitor that mimicked the cleavage site of pro-EMAPII blocked the 
release of mature EMAPII. Using tetrapeptide inhibitors and recombinant caspases, 
Behrendorf et.al showed that caspase-7 is the EMAPII cleaving protease (53). However, 
findings by Murray et.al contradicts the single critical aspartate residue concept suggested 
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by Kao et.al and disproves that caspase-7 is the primary protease that cleaves pro-
EMAPII. In vitro cleavage analysis of radio labeled 34KD EMAPII revealed several 
intermediate species suggesting that the preprotein undergoes sequential cleavage 
through the action of multiple enzymes. One possible explanation to this discrepancy in 
findings could be owing to the fact that Behrendorf et.al did not use purified pro-EMAPII 
for the assays and also they failed to employ the two heterodimers of caspase-3 and 
caspase-7(54). 
A 5’RACE was performed to assess the transcription sites of EMAPII. EMAPII 
transcription initiates at three different positions; 15 nucleotides from each other(55). 
Precursor EMAPII protein is a homolog of p43 component of the multisynthetase 
complex(56). It is also referred to as AIMP1.Pro EMAPII is related to the C-terminal 
domain of hamster p43 moiety. When multisynthetase complex was treated with caspase-
7 ,it led to the release of EMAPII and digestion of p43.It was also shown that the 
association of p43 in the complex facilitates the cleavage of this protein to EMAPII since 
purified p43 could not be completely cleaved to release EMAPII (57).AIMP1 has been 
shown to exhibit cytokine activities as well. AIMP1 induces the maturation of dendritic 
cells which in turn swings the immune response to a Th1 response (58). 
 
Figure 2: Functional domains of EMAPII and pro-EMAPII 
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The release of EMAPII is primarily associated with apoptosis and mature 
EMAPII is secreted mainly during late apoptosis. However, Pro-EMAPII is released 
constitutively even in the absence of apoptosis. Pro-EMAPII or p43 also possess cytokine 
activity in terms of TNF-α and IL-8 release. Ko et.al. speculates that cleavage of p43 to 
release EMAPII is not to activate cytokine activity but to break protein synthesis which 
would accelerate cell death (59). However, it has been shown that apoptosis is not a 
prerequisite for the release of EMAPII (60). This paves the way for a reasonable 
speculation that EMAPII is not just a by-product of p43 cleavage. It has significant 
biological functions to perform.  
Expression 
 
 EMAPII mRNA is constitutively expressed in a variety of cell lines and primary 
cells of human, murine, bovine and simian origin. Primary cells like bovine aortic 
endothelial cells and mouse embryonic fibroblasts released mature EMAPII when they 
were subjected to apoptosis (61). This was in accordance with the data obtained using 
transformed cells that released EMAPII when they were undergoing apoptosis. The 
release of EMAPII is triggered when the cells are undergoing stress, exposed to hypoxia, 
in the presence of chemotherapeutic agents or during apoptosis. However, activation of 
apoptosis is not a prerequisite for this release. Some colorectal cell lines showed cell 
surface expression of EMAPII. Both soluble and cell surface associated EMAPII are 
equally active in most of the assays. The 34-KDa form seems to be the prevalent form 
associated with the surface (60). 
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 EMAPII is expressed at high levels during embryogenesis(61-62). In mouse 
embryo, high expression of EMAPII mRNA was observed in the midbrain, the neural 
tube, areas of ossification, interdigital zones and the midgut. The areas in the embryo 
with high EMAPII expression were found to be undergoing apoptosis at a greater scale 
indicating that EMAPII co localizes with areas of high apoptosis. In an adult mouse, 
neurons of the brain, thymocytes of the thymus and germ cells of the testis showed 
increased expression of EMAPII mRNA. A high rate of apoptosis was observed in the 
thymus and testis but not in the brain. There is a strong correlation between EMAPII 
expression and apoptosis in embryonic tissues, testis and thymus. However, this 
relationship did not hold true for adult mouse brain tissue(61).Immunohistochemical 
analysis of mouse lung demonstrated that EMAPII is highly expressed in developing lung 
tissue, however its expression dwindles throughout adult life(63). 
 EMAPII expression in normal human tissues is high in tissues with high turnover 
and high protein synthesis (Figure 3). No cellular EMAPII signaling was observed in 
normal human tissues. This could be owing to the fact that EMAPII being a protein with 
proinflammatory properties, its release is tightly regulated(54). 
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System Cells and Organs EMAPII expression 
(protein) 
Cardiovascular System Smooth Muscle Cells Weak 
Endothelial cells in the heart Weak 
Blood Vessels Negative 
Gastrointestinal Tract Salivary glands: 
luminal surface 
acini 
 
Weak 
negative 
Esophagus Weak 
Peptic cells of the stomach Strong 
Parietal cells Negative 
Hepatocytes in the liver Strong 
Islets of langerhans cells Moderate 
Large and Small intestine Weak 
Respiratory Tract Lung parenchyma Negative 
Mucinous glands Negative 
Alveolar macrophages Weak 
Pneumocytes Negative 
Musculoskeletal System Skeletal Muscle 
Cartilage 
Bone 
 
Negative 
Renal System Kidney 
proximal tubules 
glomerular endothelium 
 
Moderate 
Negative 
Reproductive Organs Prostate Weak 
Seminiferous tubules Weak 
Cervixgative negative 
Endometrium Weak 
Fallopian tube Strong 
Ovary negative 
Central nervous System Neurons Strong 
Endocrine organs Thyroid gland Strong 
 Parathyroid gland negative 
Adrenal Gland moderate 
Immune System Thymus Negative 
Lymph nodes Negative 
Splenic red pulp Moderate 
Figure 3: Expression of EMAPII/pro-EMAPII in Human Tissues (Murray et al.)  
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Effect on Endothelial Cells 
 
EMAPII was isolated initially on the basis of its ability to induce tissue factor on 
endothelial cells. From then on, the effect of EMAPII on endothelial cells was 
extensively studied. This protein  brought about an increase in intracellular Ca+2 levels in 
endothelial cells which was accompanied by an increase in vWF antigen release and 
increased P-selectin expression (51). It also enhanced the expression of E-selectin 
comparable to levels expressed when endothelial cells were exposed to LPS. The 
enhanced expression of E and P selectin would indicate an increased adhesivity of 
endothelial cells for polymorphonuclear leukocytes (51). Matrigel implant and 
neovascularization model studies illustrated the ability of EMAPII to suppress neovessel 
formation in response to bovine fibroblast growth factor. This cytokine possessed 
antiangiogenic properties targeting the rapidly growing vascular beds (64-65).High doses 
of EMAPII caused complete apoptosis of endothelial cells whereas low EMAPII doses 
did not bring about a dramatic decrease in endothelial cell viability. EMAPII induced 
endothelial cell apoptosis was mediated by Fas associated death domain (FADD) protein 
up regulation  and Bcl2 protein up regulation (65).  EMAPII brought about significant 
gene expression pattern changes in endothelial cells. A total of 63 genes were up 
regulated and 6 genes were down regulated in the presence of EMAPII; DOC1,ADM, 
FOS,ICAM1,ID1,ID2,KIT, KLF4, SOCS3,TNFA and IP3 to name a few (66). Apart 
from being anti angiogenic and apoptotic for endothelial cells, EMAPII is also a chemo 
attractant (67). Endothelial cells migrate in response to increasing concentrations of 
EMAPII. The amino acid sequence that occurs at the definition site for chemokines is 
shared by EMAPII. It shares 50% sequence homology with interleukin-8 within the ten 
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amino acid long chemokine consensus region (67). Also, EMAPII-induced endothelial 
cell migration is abrogated by pertussis toxin which blocks G-protein coupled receptor 
signaling. It also increased intracellular calcium in EPC (67). These observations led to 
the conclusion that EMAPII belongs to chemokine family. After establishing that 
EMAPII is a chemokine, the next step was to deduce the receptor employed by this 
chemokine to induce EC migration.CXCR3 was the ideal candidate owing to its 
involvement in binding anti angiogenic ligands. Receptor binding competition  assays 
with EMAPII and IP10,a cognate CXCR3 ligand, demonstrated that EMAPII could 
competitively replace IP10 providing evidence for  the use of CXCR3 receptor by 
EMAPII  for signaling in endothelial cells (67). 
Effect on leukocytes 
 
EMAPII increased the cytosolic Ca+2 levels and myeloperoxidase activity in 
PMNs. EMAPII also had an effect on mononuclear phagocyte (MP) populations. In the 
presence of EMAPII, MPs released TNFα and IL-8 (51). EMAPII is chemotactic for 
polymorphonuclear cells and mononuclear cells (51). 
Recombinant EMAPII is cytotoxic to activated T lymphocytes. EMAPII caused a 
dose-dependent inhibition of Jurkat cells (activated T cell line) and had no effect on 
peripheral blood mononuclear cells (55).Recombinant EMAPII inhibits DNA synthesis 
and cell division in peripheral blood mononuclear cells. Colorectal tumor cell derived 
soluble and cell surface associated EMAPII also induced apoptosis of Jurkat cells. This 
apoptosis was associated with the activation of caspase-8 (60). 
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Regulation of EMAPII 
 
EMAPII is usually expressed in regions that are undergoing programmed cell 
death and tissue remodeling. MethA fibrosarcoma cells released mature 22Kd EMAPII 
when they were subjected to apoptosis. This release was not observed when the cells 
underwent necrosis. EMAPII mRNA expression remained unchanged when Meth A cells 
were induced to undergo apoptosis. However, as mentioned earlier, EMAPII mRNA co 
localizes at regions of macrophage accumulation and apoptosis. Thus, apoptosis might be 
one way in which EMAPII release is regulated in cells. When the cells undergo 
apoptosis, the precursor form of EMAPII is cleaved in a caspase dependent manner to 
release the mature EMAPII (62). 
Mature EMAPII is also released by tumor cells that were subjected to hypoxia. 
Hypoxia does not cause an increase in EMAPII mRNA, but causes the release of mature 
EMAPII. Hypoxic cells also displayed an increased expression of proEMAPII/p43. It was 
also observed that hypoxic cells that released EMAPII did not undergo apoptosis in 
parallel since apoptosis was one of the mechanisms that triggered the release of EMAPII. 
Moreover, release of EMAPII during hypoxia could not be inhibited by caspase inhibitors 
indicating an alternate pathway for processing proEMAPII during hypoxic conditions 
(68).Thus, hypoxia and apoptosis are the two main mechanisms by which tumors 
generate EMAPII. 
EMAPII and tumors 
 
When a solid tumor is small, it acquires the necessary oxygen and nutrients via 
simple diffusion. But when it grows larger, active angiogenesis is required for the supply 
of nutrients and oxygen. Targeting angiogenesis would therefore be an attractive 
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proposition for tumor therapy. Inhibitors targeting angiogenic factors have met with 
reasonable success as anti-tumor agents (69-70). EMAPII possess antiangiogenic 
properties and induces the apoptosis of endothelial cells. EMAPII also suppresses 
primary and metastatic tumors (64-65). These properties make EMAPII a viable 
candidate for tumor therapy. EMAPII was not cytotoxic or anti proliferative to C6 
gliomal cells in vitro. However, in vivo EMAPII therapy affected the tumor growth 
tremendously. Although, EMAPII administration did not abrogate the tumor completely, 
it led to a tremendous decrease in the tumor volume compared to the control mice that did 
not receive any EMAPII treatment (71). EMAPII also decreased the tumor proliferative 
index and brought about vascular thrombosis. The mechanism of action of EMAPII is 
different from the other antiangiogenic agents used for tumor therapy so far (71). 
Systemic infusion of EMAPII in C3H/HeJ and Balb/c mice led to systemic 
toxicity [transient inflammation] and release of cytokines whereas intratumoral injection 
led to extensive thrombohemorrhage and increased vascular permeability (51). It also 
rendered TNF insensitive tumors sensitive to the anti tumor effects of TNF, however this 
effect was observed only in vivo (51, 72). Contrary to the previously established findings, 
a prolonged course of rEMAPII treatment did not adversely affect the health of 
C57BL6/J mice. In the lewis lung carcinoma(LLC) model and human breast carcinoma 
cell line model, rEMAPII assuaged the growth of tumors without perceptible injury to 
normal organs (64).Animals injected with high EMAPII expressing melanoma cell lines 
like 1286 exhibited slower tumor growth and progression compared to those injected with 
low EMAPII expressing melanoma cell lines like PmeI (73).  Injection of retrovirally 
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transduced PmeI cell line expressing high levels of EMAPII led to slower tumor growth 
and progression. 
Having stated the properties and functions of EMAPII, I would like to shift my 
focus on another important protein STAT3. STAT3 is also a very important player in 
tumor immunology. It is therefore important to ascertain whether EMAPII could have 
any effect on STAT3 expression and functions. 
STAT3 
 
Signal transducers and activators of transcription 3 belong to the family of STAT 
proteins. These are DNA binding proteins which play an important role in dictating the 
expression of genes. STAT proteins get phosphorylated upon activation. They then leave 
the cytoplasm as homo- or hetero-dimers and translocate to the nucleus where they 
activate genes with the specific response elements (74). So far, the STAT family is 
comprised of seven members (STAT1, 2, 3, 4, 5A, 5B and 6). STAT 1 and 2 were 
identified based on interferon alpha and gamma dependent activation. STAT3 was 
identified following activation with epidermal growth factor (EGF) or interleukin-6. It 
was found that STAT3 could not be activated by interferon gamma (75). G-CSF is 
another candidate that can bring about the phosphorylation and DNA binding of STAT3 
proteins (76). 
STAT3 mRNA is highly expressed in brain, liver, kidney, testis, spleen, heart and 
thymus. Western blot of STAT3 reveals two bands; a 92KD major band and an 83 KD 
minor band. These might be alternative forms of the same protein. STAT3 shares 30 - 
40%   sequence identity with other STAT proteins (75). The deletion of STAT3 is 
embryogenically lethal and it plays pivotal roles in cell growth and division, apoptosis 
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and maintenance of homeostasis (77-78). It is a major player in controlling innate 
immunity and regulates NF-κB recruitment (78). Induction of tolerance helps to prevent 
autoimmune disorders. APCs play a very crucial role in this complex feat of imparting 
tolerance to self antigens. It has been found that STAT3 signaling is involved in inducing 
tolerogenic responses from T cells. Increased STAT3 activation in APCs resulted in 
impaired antigen specific T cell responses and abrogation of STAT3 activation led to 
autoimmunity. STAT3 seems to be a key player in maintaining the fine balance between 
tolerance and immune activation (79). 
Since STAT3 is associated with several proliferation-associated genes, cell cycle 
genes and induction of tolerance, it is not surprising for tumor cells to take advantage of 
the STAT3 pathway to benefit their survival and proliferation. Lassmann et.al found that 
there is aberrant expression of STAT3 in colorectal cancer cells. Even though the mRNA 
levels of STAT3 in neoplastic colonic epithelial cells were comparable to the normal 
epithelial cells, the mRNA levels of STAT3 inducible genes and protein levels of 
phosphorylated and unphosphorylated STAT3 were significantly higher in colonic cancer 
cells than in normal epithelial cells. This suggests that the normal regulation of STAT3 
activation is compromised in tumor cells without significantly influencing STAT3 
mRNA levels (80).Tumor also releases factors that increase the levels of activated 
STAT3 in myeloid cells. This could alter their differentiation and activation. When the 
abnormal STAT3 activation in myeloid DCs were inhibited by JSI-124, a selective 
STAT3 pathway inhibitor, DC differentiated like normal DC and exhibited a dramatic 
increase in the activation of immature DCs which was evident with an increase in the 
expression of MHCII, co stimulatory molecules and T cell activation (81).  
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Summary 
 
Even though EMAPII has been considered as a potential candidate for tumor 
therapy, the actual role played by this important cytokine in a tumor milieu is not clear.  
It was first isolated from the tumor supernatant; the actual reason as to why this protein is 
being released is not understood clearly. One of the prime reasons for this being the dual 
and contrasting functions exhibited by this protein. Some of its functions are beneficial 
for the tumor. However, some functions actually boost the immune system and aid in the 
elimination of the tumor. There could be two possible explanations: one being that it is 
released by the tumor with an agenda to interfere with the immune system in a way that 
would allow the tumor to thrive and the second reason could be that it is just a byproduct 
of another pathway, triggered accidently which now is functioning in favor of the 
immune system or the tumor.   
From the literature, the role played by dendritic cells in tumor immunology is 
absolutely evident. It will not be surprising to find tumor elaborating factors that could 
hinder the efficacy of DC. EMAPII could be one such factor released by tumor cells that 
could alter DC in such a way that would be beneficial for tumor survival. So far, the 
effects of EMAPII on dendritic cells have not been studied. The current study aims at 
elucidating the role played by EMAPII in a tumor environment with respect to its effects 
on dendritic cells. It will help us to understand to some extent whether EMAPII is 
actually playing for or against the immune system. 
As mentioned earlier, the chemotactic roles exerted by EMAPII are evident. The queries 
posed by the current research could be answered by studying the effect of EMAPII on 
dendritic cell migration, maturation, release of cytokines, phagocytosis, and pinocytosis.
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CHAPTER II 
 
EMAPII- A STIMULANT OF DENDRITIC CELL (DC) MIGRATION 
 
Introduction 
 
Being professional antigen presenting cells, the main function of dendritic cells is to 
constantly scan the environment for potential threats (1). Upon encountering such a target 
they capture them via phagocytosis or macropinocytosis (15-16). Immature DC are 
highly efficient in acquiring antigens and processing them(14). The acquired antigens are 
presented to T cells in the context of MHC molecules. CD8α lymph node resident DC are 
the key players in activating T cells during an initial infection (82). However, DC 
residing in the skin, like Langerhans cells, langerin negative dermal DC and langerin 
positive dermal DC have to migrate out of their resident zones in order to deliver the 
signals required to activate T cells in the secondary lymphoid organs (23-24). Therefore 
the migration of DC plays a very important role in immune responses and is regulated by 
chemotactic factors or chemokines released during an inflammation (83).  
 Tumors usually evade immunosurveillance by altering important immune system 
cells. They elaborate myriads of factors that could aid them in evading immune attack. 
EMAPII is one such  factor released by Meth A fibrosarcoma cells (49).EMAPII is a 
multifunctional cytokine with a multitude of important biological functions. This protein 
is thought to be released by cells undergoing stress or apoptosis (54). EMAPII is 
chemotactic for endothelial cells, polymorphonuclear and mononuclear cells 
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(51, 67). Owing to the fact that EMAPII is chemotactic for monocytes and utilizes the 
CXCR3 receptor, it is possible that EMAPII could play a role in the migration of 
dendritic cells since DC share a common progenitor with monocytes and express the 
CXCR3 receptor. 
In the present study, we evaluated whether EMAPII could induce the migration of 
DC. The effect of tumor derived and recombinant EMAPII on dendritic cells was 
determined by in vitro, ex-vivo and in vivo methods. This study shows that EMAPII may 
play a role in the disappearance/ reduction of LC/DC in tumor bearing animals. 
Materials and methods 
 
Animals 
 
BALB/c female mice aged six to twelve weeks were used for the study. 
 
Cell lines 
JAWSII cell line, an immature dendritic cell line derived from p53 growth 
suppressor gene deficient C57BL/6 mice, was purchased from ATCC (Manassas, VA). 
The methylcholantherene induced fibrosarcoma (MethA fibrosarcoma) was generously 
supplied by Dr. Wolfram Samlowski at the University Of Utah College Of Medicine. 
Media and Reagents 
JAWSII cells were cultured in RPMI 1640 medium supplemented with 5% fetal 
bovine serum, 0.002 µg/ml penicillin, 0.2 U/ml streptomycin, 2 mM glutamine and 
granulocyte-macrophage colony stimulating factor (GM-CSF). Polyclonal anti-EMAP II 
(rabbit IgG) was obtained from Oncogene Research Products (San Diego, CA) and used 
to neutralize at a final concentration of 1 µg/ml in culture. Rabbit anti-sera raised against 
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Coxiella burnetii was used as an isotype control for this antibody, a kind gift from Dr. Ed 
Shaw at Oklahoma State University. Recombinant human EMAPII was obtained from 
Biosources (Camarillo, CA).Alexa Fluor anti-langerin antibody was obtained from 
eBioscience (SanDiego, CA).Anti-mouse I-Ad antibody was purchased from Biolegend 
(SanDiego, CA). 
Tumor model  
 
For in vivo passage of the tumor, 5x 106 MethA fibrosarcoma cells in phosphate 
buffered saline were injected intraperitoneally into mice. For in vitro culture of MethA 
cells, RPMI 1640 supplemented with 10% bovine growth serum, 0.002µg/ml penicillin, 
0.02U/ml streptomycin and 2mM glutamine was used and the cells were incubated at 
37oC in a CO2 incubator. In vivo neutralization of EMAPII involved a 100µl injection of 
a 50µg/ml concentration of anti-EMAPII along with the MethA cells on day zero and a 
100µl injection of anti-EMAPII alone on day five. 
To analyze the effect of tumor burden on LC density, varying methA cell 
densities were used for intraperitoneal inoculation. 
MethA tumor supernatant 
 
MethA fibrosarcoma cells (1x105/ml) were grown in complete RPMI 1640 
medium for three days at 37oC in a CO2 incubator. Following incubation, the cells were 
centrifuged at 1500 rpm for 9 minutes at 4oC.The pellet was discarded and the 
supernatant was used for the assays. 
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In vivo assessment of LC density 
 
Mice were sacrificed and the ears were harvested. Dorsal skin was peeled off 
from the cartilage using fine forceps. The ear skin was placed dermal face down on PBS-
EDTA (0.02%w/v) for 90 minutes at 37oC.The epidermis of each section was  peeled 
using forceps and the sections were fixed in 10% buffered formalin  for 10 minutes at 
room temperature. After washing twice with PBS, sections were blocked with hydrogen 
peroxide for 15 minutes at RT on a shaker. Sections were washed thrice with PBS tween 
followed by addition of anti-Iad antibody (Pharmigen, Santiago, CA) and incubated 
overnight. After washing, freshly prepared Vectastain ABC reagent from an 
immunoperoxidase kit (Vector, Burlingame, CA) was added. VIP peroxidase substrate 
was added to develop the reaction .Sections were washed and mounted in glycerol PBS 
on a microscope slide. LC were counted with the use of a brightfield microscope to 
obtain the density. Epidermal sheets from both ears of each mouse were examined and 10 
fields per sheet were analyzed. Each experiment involved ears from at least 4 mice and 
was performed at least twice. The results consist of the mean number of IAd positive 
cells/mm2 plus or minus the standard error of the mean. In some cases, a two-tailed 
Student t-test was applied. One asterisk denotes p < 0.05 and two asterisks denote p < 
0.01. 
 In order to assess the effect of EMAPII on in vivo distribution of LC, 1µg 
recombinant EMAPII in 30µl PBS was injected subcutaneously at the base of the ear. 
Control animals received an injection of 30µl PBS. 
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Ex vivo ear skin LC migration assay 
 
LC migration was performed by following a modified procedure described by 
Schuler and Steinman(6) and enhanced by the addition of chemokine as detailed in the 
approach by Kellerman et.al (84) . Briefly, mouse ears were removed, washed in 70% 
ethanol and the dorsal skin removed by using fine forceps. The dorsal sections were 
placed split side down in 1ml complete RPMI medium for two hours. After incubation, 
skin sections were moved to fresh RPMI media with or without the tumor supernatant, 
recombinant EMAPII or polyclonal anti-EMAPII. The sections were incubated at 37oC 
with 5% CO2 for 24 hours. Emigrated cells were collected after 24hrs and the sections 
were transferred to fresh medium followed by a 24 hour incubation period. After 
incubation, both 24 hour and 48 hour samples of emigrated cells were pooled and the 
numbers of migrated Langerhans cells were determined based on DC morphology with 
the aid of a hemacytometer and brightfield microscopy. For staining with Alexa Fluor 
tagged anti-langerin antibody, the cells were fixed in 10% buffered formalin. After 
washing the cells with PBS, 60µl of 1:50 diluted anti-langerin antibody was added to the 
cells. Following incubation in the dark at RT for 45 minutes, the cells were washed four 
times with PBS. The pellet was dissolved in 100µl PBS. The numbers of langerin 
positive cells were determined using a Nikon EFD-3fluorescent microscope (Nikon, 
Tokyo, Japan). 
Transmigration Assay 
 
JAWSII cells were trypsinized. After centrifugation, the cells were dispensed in 
1000 µl sterile PBS. To test for the effect of EMAPII, 600 µl of RPMI medium with 
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sodium pyruvate, glutamine, antibiotics and serum was added to the wells of a sterile 24 
well plate. For tumor supernatant, the desired percentage was obtained using the above 
mentioned media as a diluent keeping 600 µl as the total volume. Each treatment was 
performed in duplicate. Neutralizing polyclonal anti-EMAPII antibody was added with 
tumor supernatant at a final concentration of 1µg/ml. Rabbit Polyclonal RK13 anti-
coxiella II antibody was added in conjunction with tumor supernatant as an isotype 
control. Recombinant EMAPII was added to obtain the designated concentrations. 
Transwell inserts [5.0 µm pore size] were placed in each well and cells of the JAWSII 
cell line (100µl containing 1x105 cells) were added to each insert. After Incubation at 
37oC in a CO2 incubator for 4 hours, non-migrated cells were removed by washing with 
PBS and gently scraping with a cotton swab. The inserts were stained with CAMCO’s 
fixative for 10 minutes followed by CAMCO’s staining solution for 20 minutes. The 
stained membranes were observed at 400X using a brightfield microscope and the stained 
cells were enumerated (at least 15 fields per membrane were counted).  
Results 
 
Effect of EMAPII on LC migration  
EMAPII, a multi-functional cytokine, is released by many tumor cells (50-51). 
This cytokine is chemotactic for cells of the macrophage/monocytes lineage suggesting a 
possible role in attracting dendritic cells as well (51). We investigated whether tumor 
derived EMAPII could mediate the migration of dendritic cells. Langerhans cells that are 
of myeloid origin were used in an ex vivo migration assay wherein epidermis from 
murine ear was floated on media containing Meth A supernatant with or without anti-
EMAPII. Schuler et al and Kellerman et al. have demonstrated that the majority of cells 
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that migrate out from murine ear epidermis in this model express phenotypic and 
morphological markers that are specific for Langerhans cells (6, 84). In our system, 58% 
of the cells that migrated out expressed Langerin, a LC specific marker, detected by 
immunofluorescence staining. As in Figure 4, epidermal Langerhans cells migrated more 
in response to 40% MethA tumor supernatant as compared to the medium alone. Anti-
EMAPII completely annulled the migratory stimulation exerted by the tumor supernatant. 
However, the level of migration exhibited by Langerhans cells in response to MethA 
tumor supernatant blocked with anti-EMAPII was much lower compared to the medium 
control. A possible explanation to this observation could be that tumor supernatant might 
contain anti-chemotactic factors and the effect of these factors is more pronounced in the 
absence of EMAPII. These data indicate a probability of tumor cells elaborating EMAPII 
in order to attract dendritic cells. The use of recombinant EMAPII would strengthen the 
data; however, recombinant murine EMAPII is not commercially available. Human 
EMAPII shares 86% amino acid sequence homology with murine EMAPII (51). We used 
human recombinant EMAPII to examine a dose response for migration using Langerhans 
cells. Increasing concentrations of recombinant EMAPII were used in the ex vivo 
migration assay and the number of Langerhans cells that migrated out were enumerated. 
As can be observed in figure 5, human recombinant EMAPII induced the migration of 
Langerhans cells in a dose dependent manner. 
            Figure 4: Effect of tumor derived EMAPII on Langerhans cell migration
Dorsal ear skin from Balb/c mice was floated on medium
tumor supernatant with or without neutralizing anti
that migrated out were collected after 24 and 48 hours, pooled and counted. A 
paired Student t test was employed for statistical analysis.
 
 
 
 
 
 
 
 
 
 
Dorsal ear skin from Balb/c mice was floated on medium containing increasing 
concentrations of human recombinant EMAPII. The cells that emigrated out in 
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Figure 5: Effect of recombinant EMAPII on LC Migration
34 
 containing 
-EMAPII (1µg/ml)
 
40% Tumor 
Supernatant
Tumor Supernatant 
+ Anti-EMAPII
*p<0.05
 
 
Meth A 
. The cells 
 
 
35 
 
response after 24 and 48 hour incubation periods were combined and 
enumerated. Error bars depict the standard error of the mean. 
 
In vivo assessment of LC density in tumor bearing animals 
 
Tumor cells release chemotactic factors that attract dendritic cells. These tumor 
infiltrating dendritic cells (TIDC) have impaired functions in terms of antigen 
presentation and express molecules that aid in tumor survival (40).We analyzed the 
density of Langerhans cells in tumor bearing animals. As in figure 6, we observed that 
the density of Langerhans cells in the murine ear epidermis of tumor bearing animals was 
much lower as compared to the control animals. In order to ascertain whether EMAPII 
plays a role in the observed decrease in LC density, anti-EMAPII antibody was injected 
along with methA fibrosarcoma cells on day zero and day five. Anti-EMAPII antibody 
treatment partially abrogated the effects of MethA tumor supernatant and the density of 
LC remained close to that observed in control animals. These data suggest a possible 
involvement of EMAPII in attracting dendritic cells and this cytokine being a factor 
released by tumor cells in order to accomplish this. However, anti-EMAPII did not 
completely reverse the tumor induced decrease in DC density. This could be due to other 
factors released by tumor cells that could have been repressed by EMAPII, now being 
able to exert their effects since EMAPII was blocked by its specific antibody. The data is 
representative of three independent experiments.  
                          Figure 6: In vivo assessment of LC density
Balb/c mice were injected with 
intraperitoneally, 
injections of 50µg/ml 
were harvested and the LC density on the ear epidermis was assessed by using IA 
antibody. The results are representative of three independent expe
tailed paired Student t test was performed and * indicates a p value< 0.05.
 
Effect of EMAPII on the migration of JAWSII cells
 
We observed that EMAPII could stimulate the migration of Langerhans cells both 
in vitro and in vivo. In order to 
well, JAWSII, an immature dendritic cell line
transmigration assay. JAWSII cells were seeded in the upper chamber and MethA tumor 
supernatant or recombinant EMAPII was placed in the lower chamber. The cells that 
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Effect of recombinant human EMAPII on
 
 Meth A tumor supernatant seems to be chemotactic for dendritic cells as determined 
by both in vitro and in vivo methods. Recombinant EMAPII attracted dendritic cells in ex 
vivo and in vitro assays. We wanted to determine whether the in vitro effects of 
recombinant EMAPII could be translated in vivo as well. LC density determination assay 
was performed after injecting EMAPII at the base of the murine ear. Mice were sacrificed 
after 24 hours and the density of LC in the epidermis was determined b
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can be seen in figure 8, injection of EMAPII at the base of the ear stimulated the resident 
LC to leave the epidermis corroborating the role of EMAPII in LC depletion in tumor 
bearing mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Mice were injected at the base of the ear with 1µg recombinant EMAPII or sterile 
PBS. After 24 hours, ear skin was harvested and the LC density was enumerated after 
staining the cells with IA specific antibody and immunoperoxidase system.  
Discussion 
 
 Dendritic cells contribute significantly to anti-tumor immunity. DC are potent 
stimulators of T cells and can activate tumor specific T cells (51). DC have also been 
used effectively in tumor immunization (32). However, DC are also actively involved in 
T cell tolerance induction. They play a crucial role in central as well as peripheral T cell 
tolerance (85-88). DC can present antigens derived from normal somatic cell turn over to 
T cells and induce tolerance to these self antigens that might not have been represented in 
Figure 8: Effect of recombinant EMAPII on epidermal LC 
density in vivo 
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the thymus. Owing to this dual role played by DC, it is not surprising that tumor cells 
would devise mechanisms that could alter these important immune system cells to benefit 
tumor survival. Gabrilovich et al and Idoyaga et al have shown that tumor cells affect 
dendritic cell maturation and function (35, 40). Also, tumor cells attract dendritic cells 
and these TIDC have impaired functions (40). We observed that Meth A fibrosarcoma 
cells decreased the density of Langerhans cells in the murine epidermis. However, these 
effects were limited to intraperitoneal inoculation of Meth A tumor since subcutaneously 
implanted Meth A tumor did not decrease the LC density in the periphery. This suggests 
that tumor would exert systemic effects on DC only after the tumor is well established 
and when the tumor burden is high. This is in conjunction with our observation that LC 
density decreases with an increase in the MethA tumor density at the time of inoculation 
(data not shown). The decrease in LC density could be attributed to multiple factors. A 
role of apoptosis could be ruled out since we have proven that neither MethA tumor 
supernatant nor EMAPII could bring about the apoptosis of dendritic cells in vitro. It 
could be argued that the reduction in LC density is due to the decrease in the influx of LC 
precursors necessary to populate the epidermis. However, this argument cannot hold true 
due to the existence of resident LC precursors in the skin. There is also a possibility that 
LC are leaving the epidermis and are migrating to the lymph nodes or to the tumor.  
 As mentioned earlier, tumors elaborate factors that could affect dendritic cell 
maturation and functions and the majority of tumors may attract dendritic cells due to 
their possible role in T cell tolerance. EMAPII has been shown to be secreted by Meth A 
fibrosarcoma cells (50). This multi-functional cytokine is chemotactic for monocytes and 
we wanted to determine whether EMAPII is a factor released by methA fibrosarcoma 
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cells to attract dendritic cells. We hypothesized that EMAPII could be chemotactic for 
dendritic cells based on the fact that most dendritic cells share the same myeloid lineage 
of monocytes and that EMAPII utilizes CXCR3 receptor which is one of the receptors 
utilized by dendritic cells for chemotaxis (67, 89-90). Our data demonstrates a clear role 
of both tumor derived and recombinant EMAPII in the decrease in epidermal LC density. 
The final destination of the skin resident LC is not clear and needs to be determined. In 
our in vitro studies, we demonstrated that the chemotactic effects of Meth A supernatant 
could be extended to other myeloid derived dendritic cells like JAWSII cells.  
 The fact that only 58% of the cells that migrated out from the skin explants was 
langerin positive could be attributed to the fact that LC that migrate out from skin 
explants display a mature phenotype and langerin expression is down regulated in mature 
Langerhans cells (91-92). An alternate explanation could be that EMAPII is chemotactic 
for both epidermal and dermal dendritic cells since the cells migrated out exhibited 
typical dendritic cell morphology and IA expression. The ability of recombinant EMAPII 
to reduce the LC density when injected at the base of the ear provides indisputable 
evidence supporting the chemotactic role played by EMAPII in dendritic cell migration. 
According to our study, this multi-functional cytokine can stimulate the migration of 
dendritic cells belonging to the myeloid lineage and it is one of the factors employed by 
Meth A fibrosarcoma cells to attract dendritic cells. The fact that anti-EMAPII could not 
completely reverse the tumor induced decrease in DC density in the periphery suggests 
that tumor cells are elaborating factors anti-chemotactic that are repressed in the presence 
of EMAPII. 
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 However, it is uncertain whether the dendritic cells are attracted to the tumor or they 
are routed to the nearest draining lymph node. Further studies need to be conducted to 
determine the effects of this cytokine in terms of dendritic cell maturation and functions.
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CHAPTER III 
 
EFFECT OF EMAPII ON DENDRITIC CELL FUNCTIONS 
 
Introduction 
 Dendritic cells play a very important role in the induction of peripheral tolerance 
(93-94). When cells undergo apoptosis, auto antigens become chemotactic and attract 
immune system cells like dendritic cells to clear up the debris without evoking an 
immune response thereby preventing autoimmunity (95). The dendritic cells that reach 
these sites are tolerogenic in nature and thus aid in peripheral tolerance. EMAPII, a 
multifunctional cytokine first isolated from the supernatant of MethA fibrosarcoma cells, 
is released upon apoptosis. EMAPII is chemotactic for dendritic cells, as shown in 
chapter II, suggesting a possible role played by this cytokine in peripheral tolerance. The 
mechanisms in place for preventing autoimmunity can often be exploited especially in the 
case of tumors. Tumors can manipulate the mechanism of tolerance induction to benefit 
their survival. EMAPII could be one such factor released by cells undergoing apoptosis to 
alter dendritic cell functions, and in a tumor environment EMAPII could be working in 
favor of tumor survival by preventing an auto immune response. In order to ascertain this, 
it is important to determine whether EMAPII can alter DC functions to render them more 
tolerogenic.  
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Materials and Methods 
 
Animals  
BALB/c female mice aged six to twelve weeks were used for the study. 
Cells and Cell lines 
JAWSII cell line, an immature dendritic cell line derived from p53 growth 
suppressor gene deficient C57BL/6 mice, was purchased from ATCC (Manassa, VA).  
The methylcholantherene induced fibrosarcoma (MethA fibrosarcoma) was generously 
supplied by Dr. Wolfram Samlowski at the University of Utah College of Medicine. 
Saccharomyces cerevisiae PJ69-4A was a kind gift from Dr.Jeff Hadwiger (Oklahoma 
State University). 
 Generation of bone marrow derived dendritic cells (BMDC) 
BMDC from Balb/c mice were harvested by using a protocol described by Wong et al. 
and Matheu et al. with modifications (96-97). Briefly, after sacrificing the mice by carbon 
dioxide asphyxiation, the femurs were obtained.  The bones were cleaned and placed in 
75% ethanol for ten minutes. The bones were then transferred to RPMI1640 medium 
supplemented with 5% fetal bovine serum, 0.002 µg/ml penicillin, 0.2 U/ml 
streptomycin, 2 mM glutamine. Using a 1ml 26G3/8 syringe, bone marrow was forced 
out of the bones by flushing the femur four or five times with the media into a 20 X 
15mm petriplate containing 15 ml medium. Cells were disrupted by pipetting to obtain 
single cell suspension. The cell suspension was transferred to a 50 ml centrifuge tube, the 
petriplates were washed with 10ml medium three times and the suspension was 
centrifuged at 1500 rpm at 4oC for nine minutes. The supernatant was discarded followed 
by RBC lysis. For lysing RBCs, 900 µl sterile distilled water was added to the cells. 
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Within few seconds, 100 µl sterile PBS and 1ml RPMI medium was added. The cells 
were centrifuged again and the pellet was resuspended in four milliliters RPMI 1640 
medium with 10 ng /ml GM-CSF [Primary DC medium].Cells were plated at 1x106 
cells/ml in primary DC medium and incubated at 37oC in a CO
 2 incubator. On day four, 
after removal of the medium, 10 ml fresh primary DC medium was added to the cells. On 
day seven, cells in suspension were collected, centrifuged, resuspended in 1ml primary 
DC medium and returned to the original plates with adherent DC. Fresh DC medium was 
added to the plates followed by incubation at 37oC in a CO
 2 incubator. Cells were 
harvested on day 10 and used for further analysis and experiments. 
Media and Reagents 
JAWSII cells were cultured in RPMI 1640  medium supplemented with 5% fetal 
bovine serum, 0.002 µg/ml penicillin, 0.2 U/ml streptomycin, 2 mM glutamine and 5-10 
ng/ml granulocyte-macrophage colony stimulating factor(GM-CSF). MethA 
fibrosarcoma cells were cultured in RPMI 1640 supplemented with 10% bovine growth 
serum, 0.002 µg/ml penicillin, 0.02 U/ml streptomycin, 2 mM glutamine. Yeast cells 
were grown in YEPD media: 10 g yeast extract, 20 g dextrose (glucose) or 40 ml 50% 
glucose solution, 20 g Bacto-Peptone (Difco) and 1 liter nanopure H2O. Anti-mouse 
VEGF antibody was purchased from R&D Systems (Minneapolis, MN).Neutral red 
solution used for pinocytosis was bought from SIGMA (USA). 
Viability assay 
  
JAWSII cells at a density of 1x105/ml were incubated at 37oC in the presence of 
MethA tumor supernatant for 24 hours. Cells treated with cyclohexamide were used as 
the positive control. Following incubation, the plates were centrifuged at 500 rpm for five 
45 
 
minutes. After removal of the medium, 100 µl of MTT [3-(4, 5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] solution (5 mg/ml stock) diluted in complete RPMI 
medium (1:5 dilution) was added to the wells. The plates were incubated at 370C for six 
hours. The plates were centrifuged at 500 rpm for five minutes. The fluid from the wells 
was aspirated out and 100 µl isopropanol was added to each well. The purple formazan 
crystals were dissolved by pipetting vigorously 15 times. The plates were read at 630 nm 
in the EL-800 microplate reader (Biotek instruments, VT, USA). The absorbance in the 
medium blank wells was subtracted from each absorbance reading.  
Pinocytosis Assay  
 
A modification of pinocytosis assay described by Weeks et.al (98)was followed. 
JAWSII (1x106 /ml) cells were incubated on a shaker platform at 20±2oC in JAWSII 
growth medium with or without EMAPII (0.5 µg/ml), with or without 50% methA tumor 
supernatant, and 50 µg neutral red for two hours. Serum –free (SF) methA tumor 
supernatant was also assayed. Each treatment was performed in duplicate. After 
incubation, cells were centrifuged and the pellet was washed in 5ml Phosphate buffered 
saline (PBS) at 200 x g for five minutes. The pellet was resuspended in 2.5ml acid 
alcohol (3% HCL in 95% ethanol). After centrifugation to clear debris, the supernatant 
was diluted with complete RPMI 1640 medium. The percent transmittance at 533nm was 
determined using a Schimadzu UV-VIS scanning spectrophotometer (TX, USA). RPMI 
1640 medium with 50% acid alcohol was used as the blank for the transmittance 
measurements. A standard curve was plotted using different neutral red concentrations 
and the amount of neutral red pinocytosed was derived from the standard curve and 
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corrected for cell numbers (total µg neutral red per 106 cells). Refer to Appendix 2 for 
calculations and standard curve. 
Phagocytosis Assay 
Yeast suspension 
Saccharomyces cerevisiae PJ69-4A was grown in PYED broth in a shaker at RT. 
The yeast cells were pelleted and counted using the trypan blue dye exclusion method. To 
1x108 yeast cells, 3ml of 0.87 %( w/v) congo red was added. The suspension was allowed 
to stand for five minutes, 7 ml distilled water was added and the solution was autoclaved 
for 20 minutes. The yeast cells were then washed with sterile PBS, resuspended in sterile 
PBS and counted using a hemacytometer. 
JAWSII /BMDC cell treatment 
JAWSII cells or BMDC at a density of 2.5 x 105/ml were incubated with or 
without EMAPII (0.5µg/ml) in primary DC medium for 24 hours in 24 well plates. 
Untreated cells were used as control. 
Assay 
A modification of phagocytic assay proposed by Kaminski et.al (99)and Walsh et 
al. was followed (100). Briefly, 100 µl of stained yeast suspension (1.5x 107 cells) was 
added to the treated and control JAWSII cells or BMDC. The set-up was incubated at 
370C for 90 minutes. Following incubation, the wells were rinsed with sterile PBS. After 
addition of 1ml sterile PBS, the cells were observed under a brightfield microscope at 
400X.  JAWSII/BMDC from random fields were assessed (a total of 100) and the 
numbers of yeast cells phagocytosed by the cells were counted.  
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Cytokine profiling 
 
Analysis of cytokine transcripts 
RNA Extraction 
BMDC were cultured at a concentration of 1x106 cells/ml in primary DC growth 
media with or without recombinant EMAPII (0.5µg/ml) at 37oC in a 5% CO2 incubator 
for four hours. A total of three biological replicates for control and treatment groups were 
set up. Following incubation, the cells were collected by using a cell scraper, centrifuged 
briefly to pellet the cells and RNA was extracted from the cells using Qiagen’s RNeasy 
kit. RNA was eluted from the spin filter using RNAse free water. After obtaining the 
concentration and purity of the RNA sample using a NanoDrop ND-1000(s) 
spectrophotometer (WI, USA), RNA samples were treated with Deoxyribonuclease I 
(Invitrogen, CA,USA). Briefly, 0.5µg RNA was treated with 1µl DNase buffer and 1µl 
DNase for 15 minutes at R.T. DNAse was then inactivated by heating at 65oC for ten 
minutes in the presence of 25mM EDTA. 
cDNA Synthesis 
DNase treated samples were used for cDNA synthesis with Qiagen’s Quantitect 
Reverse Transcription kit following the manufacturer’s protocol. Briefly, 0.5 µg DNase 
treated RNA samples were incubated with genomic DNA wipeout buffer for two minutes 
at 42oC followed by incubation with reverse transcriptase master mix at 42oC for 30 
minutes. The enzyme was inactivated by incubating the reaction mixture at 95oC for three 
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minutes. An MJ Research PTC220 thermocycler (Biorad, CA,USA) was used for the 
reaction.  
 
Cytokine Array 
SABiosciences RT2Profiler PCR Array system was used to analyze the expression 
of 84 different genes after EMAPII treatment. Briefly, cDNA synthesized by using the 
above mentioned protocol was diluted with DNase free water to a total volume of 102 µl. 
SABiosciences  RT2qPCR 2X master mix was added to the diluted cDNA sample and the 
total volume was made up to  2550 µl. The experimental cocktail [25 µl] was dispensed 
in all 96 wells of the PCR array plate, the plate was sealed and centrifuged at 500 rpm for 
15 minutes. The PCR array plate was run in an Eppendorf  Mastercycler using the 
following cycling conditions: 95oC for 10 minutes, 95oC for 15 seconds, 60oC for 1 
minute with a final infinite hold at 4oC . The results obtained were uploaded onto 
SABiosciences Web portal software in order to calculate the fold regulation and statistics. 
Ct value is the cycle at which fluorescence crosses the set threshold value. The Ct values 
of each gene of interest (GOI) were standardized against Glucoronidase B by subtracting 
the Average Ct of Glucoronidase B from the average Ct of GOI to obtain ∆Ct.  ∆∆Ct was 
then calculated by subtracting the ∆Ct of control/untreated sample from the ∆Ct of 
EMAPII treated sample. Fold change was obtained by 2-∆∆Ct  method.  
T Cell Chemotaxis Assay 
JAWSII cells were grown in the presence of sterile PBS or 0.5 µg/ml recombinant 
EMAPII for 24 hours at 37oC. Following incubation, the cells were centrifuged and the 
supernatant was collected. Supernatant form both treated and untreated JAWSII cells 
were blocked with neutralizing anti-EMAPII antibody for thirty minutes at 37oC. Jurkat T 
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cells (a kind gift from Dr. Gurunadh Chichli, OMRF) were seeded in transwell inserts (5 
µm pore size) and the supernatant from JAWSII cells, used as the chemoattractant, was 
loaded in the bottom chamber. T cells were allowed to migrate for four hours at 37oC. All 
the cells that migrated to the bottom well were collected, centrifuged and enumerated 
using a hemacytometer.   
IL-10 Assay 
Mouse IL-10 Quantikine immunoassay kit (R&D Systems, USA) was used to 
assess IL-10 released by JAWSII cells. JAWSII cells, 2x105, were incubated with or 
without 5 µg LPS/ 5 µg recombinant EMAPII for 48 hours. The cells were centrifuged at 
1500 rpm for nine minutes. The supernatant was collected and used for the assay. 
 Briefly, 50 µl of the supernatant was added to quantikine ELISA plates with the 
assay diluent. Mouse IL-10 kit control was used as the positive control and calibrator 
diluent was used as the negative control. After two hours incubation, the wells of the 
ELISA plate was washed five times followed by addition of 100 µl of IL-10 conjugate. 
The plate was incubated for two hours. Following incubation and washing, 100 µl 
substrate was added to the wells and incubated in the dark. Stop solution was added after 
30 minutes and the optical density was measured using EL-800 microplate reader (Biotek 
instruments) at 450nm.  
Proteome Array 
Proteome ProfilerTM Mouse Cytokine Array panel [R&D Systems, MN, USA] 
was used to analyze the expression of 40 different analytes following EMAPII treatment. 
JAWSII cells at a concentration of 1.2X106 was incubated in JAWSII growth medium 
with or without recombinant EMAPII [1.73 µg final concentration] for 48 hours at 37oC 
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in a CO2 incubator. After the period of incubation, cells and the medium were centrifuged 
for 20 seconds and the supernatant was collected and used for the assay. The assay was 
carried out following the manufacturer’s protocol. Briefly, 600 µl of the sample was 
incubated with buffer 4, buffer 5 and detection antibody cocktail from the array kit at 
20±2oC for one hour. The mixture was added to blocked nitrocellulose arrays and 
incubated overnight on a shaker platform at 4oC.Following subsequent washes and 
incubation with Streptavidin HRP, the nitrocellulose membrane was developed using 
chemiluminescent detection substrate (USBiological, Massachusetts, USA). An 
AlphaInnotech HP Imager ( AlphaInnotech, CA, USA)was used to develop the blots. 
Data was analyzed using the Image J software (NIH).  
STAT3 Expression and Activation 
Western Blot  
Sample Preparation  
 JAWSII cells at a concentration of 1x106/ml  were subjected to GM-CSF 
starvation by growing the cells in JAWSII growth medium without GM-CSF for 24 
hours. The cells were then incubated in the presence or absence of 1 µg EMAPII or PBS 
or 1 µg LPS for four hours at 37oC in a CO2 incubator. Lysates from JAWSII/BMDC 
treated with 1µg LPS and from HeLa cells treated with INF-α were used as positive 
controls. After incubation, the cells were scraped using a cell scraper, centrifuged at 
12000 rpm for 20 seconds. To the pellet, 100 µl RIPA lysis buffer with sodium 
metavanadate , sodium azide, PMSF, benzaminidine and aminocaproic acid was added. 
The cell suspension was incubated at 4oC for 30 minutes on a shaker platform. The 
suspension was centrifuged, the supernatant was carefully collected, stored at -20oC and 
used for the assay. Protein concentration of the lysates were determined by using a 
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Bradford Assay(101). Briefly, 0.8 ml 1:4 diluted Bradford reagent was mixed with 2 µl of 
the cell lysate. The suspension was mixed thoroughly by vortexing and incubated at 
20±2oC for two minutes. A blank consisted of 2 µl lysis buffer and 0.8 ml diluted 
Bradford reagent. Optical density at 600nm was determined using Schimadzu UV-VIS 
scanning spectrophotometer (TX, USA). Protein concentration was determined by using 
the following formula: 
Protein Concentration in µg/µl = Absorbance at 600nm X 10 
PAGE and Western Blot 
A reducing PAGE gel with 5% stacking and 10 % resolving gel was used for the 
separation of proteins. Kaleidoscope Precision Plus marker (Biorad, USA) was used as 
the protein ladder. 40 µg of the protein lysate was loaded and the gel was run at 120 
volts. After separation, the proteins were blotted onto a nitrocellulose sheet. Blotting was 
done overnight at 4oC at 30 Volts. After transfer, the nitrocellulose membrane was 
stained with 0.1% amido black solution in 10% Glacial Acetic Acid for one minute on a 
rotating shaker and destained at 20±2oC for 20 minutes. The blot was then photographed 
UVP GelDoc It Ts Imaging System (Upland, CA). Following destaining, the blot was 
blocked in blocking buffer for 1 hour at 20±2oC followed by overnight incubation at 4oC. 
The blot was incubated in 1:2000 diluted rabbit polyclonal anti-mouse STAT3 phospho 
Y705 antibody (Abcam,USA) at 4oC overnight. The blot was washed four times for ten 
minutes each with wash buffer. 1:2000 diluted anti-rabbit IgG  horse radish peroxidase  
was used as the secondary antibody. The blot was incubated with secondary antibody for 
one hour at 20±2oC. Following incubation, the blot was washed four times with wash 
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buffer. The blot was developed by adding 2 ml chemiluminescent substrate 
(USBiological, Massachusetts), USA) for horse radishperoxidase enzyme and exposing 
to AplhaInnotech HP imager.  
Cell Surface Marker Expression 
Flow Cytometry 
Sample Preparation 
BMDC were seeded at a concentration of 1.2X106 in complete growth medium 
with or without 5 µg/ml LPS and/or 1 or 2 µg/ml recombinant EMAPII. Untreated 
control cells received sterile PBS instead of EMAPII or LPS. The cells were incubated at 
37oC in a 5% CO2 incubator for 48 hours. Following incubation, the cells were scraped 
using a cell scraper and centrifuged at 10,000 rpm for 5 seconds. Pelleted cells were fixed 
by incubating with 10% buffered formalin for ten minutes. The cells were washed with 
PBS and resuspended in 500 µl of filter sterilized PBS-sodium Azide-Bovine Growth 
Serum (BGS) solution. The cells of each treatment were stained for CD80, CD86 and I-A 
expression. Cells were double stained for I-A and CD80. To the 500µl cell suspension of 
treated and untreated cells, 12µl of 1:100 diluted Fluorescein Isothiocyanate (FITC) 
conjugated anti-mouse MHCII (I-A/I-E) antibody(eBioscience, SanDiego, CA)  and 30 
µl of 1:100 diluted  Phycoerythrin (PE) conjugated anti-mouse CD80 antibody 
(eBioscience, SanDieigo,)was added to obtain a final antibody concentration of 0.06 
µg/ml. For staining CD86, 12 µl of 1:100 diluted anti-mouse CD86 FITC conjugated 
antibody was added to the cell suspension separately. Isotype controls for the antibodies 
were purchased from eBioscience and included PE Armenian Hamster IgG isotype 
control and FITC Rat IgG2b isotype control. The cells were incubated with the antibodies 
at 20±2oC in the dark on ice for 30 minutes. Cell suspension was then slowly layered 
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over 1 ml bovine growth serum (BGS) and centrifuged at 1500 rpm for five minutes. The 
pellet was dissolved in 500 µl PBS-Sodium Azide-BGS solution and analyzed by using a 
Becton Dickinson FACSCalibur flow cytometer (NJ, USA).  
Results 
 
Viability Assay 
The release of mediators that would bring about the apoptosis of important immune 
system cells actively involved in tumor immunity would be beneficial for the tumor. The 
effect of Meth A fibrosarcoma tumor supernatant on the viability of JAWSII cells was 
assessed using the Method of Transcriptional and Translational assay (MTT). The assay 
is based on the ability of live cells to reduce MTT to purple formazan crystals. Tumor 
supernatant at concentrations of 50% and 80% were used for the analysis. Tumor 
supernatant was tested initially as a primary screen. If tumor supernatant induced JAWSII 
cell death, EMAPII would have been tested to ascertain whether the tumor releases 
EMAPII to induce DC cell death. Cyclohexamide [a potent protein inhibitor] was used as 
a positive control for cell death. The results are summarized in Figure 9. MethA tumor 
supernatant at 50% and 80% concentrations did not affect the viability of JAWSII cells. 
Treatment with cyclohexamide completely abrogated growth and viability of JAWSII 
cells.  Compared to the medium alone control, the OD of 50% and 80%  MethA 
supernatant treatment , 0.791 and 0.701 respectively, did not significantly differ implying 
that the factors released by MethA tumor supernatant did not adversely affect the 
viability of DC. There is a possibility that tumor supernatant contains growth stimulating 
factors that is suppressing the effects of the growth inhibitors. 
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JAWSII cells (1x105/ml) were incubated with methA tumor supernatant for 24 
hours. The treated cells were then incubated with MTT for six hours. 
Cyclohexamide was used as positive control for cell death. The OD of purple 
formazan crystals solubilized in isopropanol after the six hour incubation period 
was determined at 630nm using a microplate reader. 
Effect of EMAPII on DC Pinocytosis 
Dendritic cells are potent antigen presenting cells. They take up antigens by 
micropinocytosis, macropinocytosis and phagocytosis (15-16). Some of these antigens 
are acquired by receptor mediated endocytosis as well. Since pinocytosis is one of the 
classic functions of dendritic cells, it is important to determine whether EMAPII affects 
the ability of DC to pinocytose. A modification of pinocytosis protocol described by 
Weeks et.al was followed. In order to eliminate the possibility of serum proteins affecting 
the pinocytic ability of DC, supernatant from MethA cells grown in serum-free RPMI 
1640 medium was also used as a control. JAWSII cells in the presence of 50% MethA 
tumor supernatant had reduced pinocytic abilities as compared to control cells incubated 
in the absence of tumor supernatant as evidenced in figure 10. From the graph, it is clear 
Figure 9: Viability Assay 
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that serum proteins did not influence the pinocytosis of JAWSII cells. Since, MethA 
tumor supernatant reduced the pinocytosis of DC; the experiment was repeated with 
recombinant EMAPII to ascertain whether EMAPII was the agent present in the tumor 
supernatant that caused a reduction in pinocytosis. EMAPII did not abrogate the 
pinocytosis of JAWSII cells (Figure 11). Even though, the neutral red accumulated by 
EMAPII treated JAWSII cells were lower compared to the control cells, there was no was 
no significant reduction and the effect was not as pronounced as tumor supernatant 
treatment. This data suggest that EMAPII does not directly affect the pinocytic abilities 
of dendritic cells and it is not the factor employed by tumor cells to reduce the pinocytic 
abilities of dendritic cells.  
 
 
 
                        
 
 
 
                  Figure 10: Effect of MethA supernatant on JAWSII Pinocytosis 
JAWSII cells at a concentration of 1x106 /ml were incubated in the presence of 
50% Meth A supernatant with or without serum and 50 µg neutral red for 2 
hours. Following incubation, the pellet was resuspended in acid alcohol and the 
debris was cleared by centrifugation. The supernatant obtained was diluted in 
complete RPMI1640 medium and the percent transmittance of the solution at 
533nm was determined using UV-VIS scanning spectrophotometer and was used 
to calculate the amount of neutral red taken up by 106 JAWSII cells.  
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The effect of EMAPII on JAWSII pinocytosis was assessed by incubating1x106 /ml 
JAWSII cells in the presence of 0.5 µg/ml EMAPII and 50 µg neutral red for two 
hours and measuring neutral red intake. The cells were washed with acid alcohol 
and centrifuged and the supernatant was diluted with complete RPMI 1640 
medium. The transmittance at 533nm was measured and was used to calculate the 
amount of neutral red taken up by 106 JAWSII cells. 
Effect of EMAPII on DC phagocytosis 
Dendritic Cells, being professional antigen presenting cells, capture and process 
antigens in order to present them to T cells or to engage other immune system cells. 
Phagocytosis is an endocytic  process by which cells like DC capture large antigens 
through an actin dependent mechanism (102). JAWSII cells and BMDC were both tested 
for their ability phagocytize after treatment with EMAPII for 24 and 48 hours. The 
number of yeast cells phagocytized by each phagocyte was enumerated and the 
phagocytic index was calculated (Figure 12, 13). Phagocytic index is the average number 
of cells engulfed per antigen presenting cell/phagocyte. The percentage of DC that  
Figure 11: Effect of EMAPII on JAWSII pinocytosis 
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exhibited more than 5 yeast cells within the cytoplasm was also assessed (Figure 14, 15). 
EMAPII treated DC (JAWSII and BMDC) exhibited low phagocytic indices compared to 
the untreated Control cells. The number of yeast cells that could be phagocytosed by DC 
was also reduced when the cells were treated with EMAPII. This was evidenced in figure 
14 and 15 where the percent of DC that captured more than 5 yeast cells was very low 
compared to the untreated controls. EMAPII treatment however did not completely 
abrogate the ability of DC to phagocytize.  
 
 
 
 
 
 
The JAWSII cells/BMDC ( 2.5x105)  were treated with EMAPII for 24 hours ,the 
treated cells were incubated with heat killed stained yeast suspension and the 
phagocytic index was determined by counting 100 dendritic cells after 90 minutes 
using a brightfield microscope. The figure is a representative of three/ four 
identical experiments. * p=0.0075 for the JAWSII trial and 0.0158 for BMDC 
trial.  
Figure 13: The effect of EMAPII on 
JAWSII Phagocytic Index 
Figure 12: The effect of EMAPII 
on BMDC Phagocytic Index 
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JAWSII cells/BMDC (2.5x105/ml) were treated with EMAPII for 24 hours, the 
treated cells were incubated with heat killed stained yeast suspension and the 
number of yeast cells phagocytosed by JAWSII and BMDC after EMAPII 
treatment was enumerated. The percentage of dendritic cells that engulfed more 
than five yeast cells was determined. The graph is a representative of three 
identical experiments. *p=0.0043 for BMDC trials and 0.0018 for JAWSII trial. A 
paired Student T test was used for statistical analysis. 
The reduction in DC phagocytic index in the presence of EMAPII indicates that 
EMAPII interferes with the phagocytic pathway probably giving tumor cells an 
advantage by reducing the chances of tumor associated antigens to be phagocytosed 
effectively by dendritic cells. Also, the observation that the percentage of DC that take up 
less than five yeast cells when treated with EMAPII suggests that EMAPII is down 
regulating receptors that are required for effective uptake of the antigens. 
Cytokine Profiling 
 
As antigen presenting cells, dendritic cells are the key players to activate naïve T cells. T 
cells mature upon receiving maturation signals which could be the cytokines released by 
Figure 15: The effect of EMAPII  
on JAWSII Phagocytosis 
Figure 14: The effect of EMAPII on 
BMDC Phagocytosis 
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the APC upon their interaction with a T cell and this interaction is mediated by 
chemokines. DC are capable of releasing myriads of cytokines and based on the 
surrounding environment, some cytokines are up regulated and some are down regulated. 
Based on the cytokines they are exposed to, T cells can become regulatory T cells or 
follow a Th1 or Th2 lineage. The effect of EMAPII on dendritic cell cytokine profile was 
assessed to determine whether tumor elaborates this cytokine to affect the DC in ways 
that would alter their normal cytokine function which would abrogate the functions of 
cells involved in anti-tumor immunity. Cytokine transcripts in DC with or without 
EMAPII treatment was determined by using a Cytokine profiler kit which could test for 
84 different cytokine transcripts and five housekeeping genes. GusB or beta 
Glucoronidase was used for normalizing the data since some of the other housekeeping 
genes like actin were up regulated after EMAPII treatment. Interestingly, the cytokines 
that were affected by EMAPII treatment that exhibited statistically significant fold 
changes were all down regulated. Figure 16 tabulates the fold regulation of cytokine gene 
expression after EMAPII treatment and the average delta Ct values of the genes that 
showed statistically significant change in gene expression is graphed in Figure 17. Ct 
value or threshold cycle is the cycle at which fluorescence crosses the set threshold value. 
Delta Ct is the difference between the Ct values of the gene of interest and the house 
keeping gene (in our case GusB). Average delta Ct is the average of the delta Ct obtained 
from three biological replicates.  
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BMDC (1x10 6cells/ml) were incubated in the presence of 0.5 µg/ml EMAPII for 
four hours. Following RNA extraction, a cDNA synthesis kit was used to reverse 
transcribe mRNA to cDNA. cDNA was mixed with the SABiosciences RT2 qPCR 
mastermix and dispensed in the PCR array plate. After 40 cycles, delta Ct values 
and fold change values were calculated using the Web portal software available 
through the manufacturer’s website. A fold change of 2 and above was considered 
a significant change in gene expression. 
 
Figure 16: Fold Regulation of Cytokine transcripts expressed by BMDC after 
EMAPII treatment 
 Fold regulation 
changes and a twofold regulation
untreated control 
and below was considered
T cell Chemotaxis Assay
Down regulation of CXCL9, CXCL11 and CXCL12 transcripts would decrease 
the chemotaxis of T cells in response to dendritic cells. In order to determine whether the 
results obtained at transcript levels could be translated physiologically as well, a T cell 
migration assay in response to dendritic cells treated with EMAPII was performed. 
JAWSII cells were incubated in the presence 
supernatant obtained from the cultured cells analyzed for their ability to attract T cell
Since EMAPII is apoptotic for lymphocytes
the supernatant was treated with neutralizing anti
neutralize EMAPII present in the supernatant. Supernatant from both untreated c
and EMAPII treated cells were neutralized before the chem
in figure 18, supernatant from DC treated with EMAPII showed 
-7.7633
-9 -8 -7
Effect of EMAPII on BMDC cytokine transcripts
Figure 17
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 after EMAPII treatment when compared to 
is plotted. A Student t test was employed and a p value of 0.05 
 statistically significant. 
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being a reason for this reduction can be ruled out since EMAPI
specific antibody. This again would be advantageous to the tumors since blocking 
chemotaxis of T cells would enhance the chances of tumor survival and
This corroborates our earlier finding that EMAPII treatment reduces chemokines like 
CXCL9, CXCL11 and CXCL12 that are chemotactic for T cells. 
 
 
 
 
 
 
 
 
 
Figure 
JAWSII cells (1x10
24 hours. The supernatant from these cells were assayed for their ability to attract 
T cells in transmigration assay. T cells
chamber and the supernatant was 
cells that migrated to the bottom chamber was enumerated
using a hemacytometer and a brightfield microscope.
three independently conducted experiments.
 
IL-10 Assay 
IL-10 exerts several effects on APC such as macrophages, monocytes and 
dendritic cells. IL-10 abrogates MHCII, CD86 and CD58 expression on dendritic cells. It 
renders the DC ineffective in terms of inducing T cell responses of primed and naïve T 
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cells. In addition, IL-10 treated DC induced an anergic response from CD4+T cells (103). 
The ability of EMAPII to induce the release of IL-10 from dendritic cells was assessed by 
performing an ELISA to detect picogram quantities of IL-10 released after EMAPII 
treatment. As in figure 19, Meth A supernatant and LPS induced the release of IL10. 
However, EMAPII treatment did not induce IL10 production. In conjunction with LPS or 
Meth A supernatant, EMAPII augmented the release of IL10 in response to these agents. 
But this was not a very significant change. One of the reasons why EMAPII could 
increase the release of IL10 in response to the tumor supernatant could be that EMAPII is 
antagonistic to some of the IL10 inhibitors thereby suppressing their effects to a greater 
extent.   
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IL-10 release from JAWSII cells was assessed by an ELISA based method wherein 
2x10 5 JAWSII cells/ml were incubated in the presence or absence of EMAPII 
and/or LPS/ MethA tumor supernatant for 48 hours and the supernatant was 
assayed for IL-10.* indicates a p value >0.05. 
Proteome Array 
The profile of cytokines released by dendritic cells play an important role in shaping the 
immune response. We wanted to determine whether treatment with EMAPII changed the 
cytokine profile of dendritic cells. At transcript levels, we observed that EMAPII down 
regulated the expression of many important cytokines. To ascertain whether this effect is 
translated at protein levels as well, we used a proteome profiler array to measure the 
cytokine secretion after EMAPII treatment and compare with untreated controls.  JAWSII 
were employed for the purpose. As can be seen in figure 20, EMAPII treatment changed 
the cytokine profile of JAWSII cells. The representative of two experiments is shown in 
figure 20. EMAPII treatment lowered the cytokine levels of JAWSII cells. I309, eotaxin, 
IL1 beta, Il3, IL5, IL7, IL12, M-CSF and MIP-1 alpha were some of the cytokines whose 
Figure 19: Quantification of IL-10 release by ELISA 
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expression was significantly down regulated. The levels of these cytokines were less than 
50% in comparison to the controls.  It is interesting to note that the cytokines that were 
down regulated by EMAPII were all pro inflammatory cytokines there by assuaging the 
chances of an anti tumor immunity to develop.   
 JAWSII cells at a concentration of 1.2x106 /ml were incubated in the presence or 
absence of EMAPII for 48 hours. The cells were centrifuged and the supernatant 
was used for the analysis. Nitrocellulose membranes blotted with antibodies 
against the 40 analytes to be tested was incubated with the supernatant. The blot 
was developed using a chemiluminescent substrate. Chemiluminescent signals 
obtained from the blots were measured using the Image J software and the 
integrated pixel densities were obtained. Normalization was done by multiplying 
the integrated pixel density values by a factor obtained by comparing the average 
pixel densities of the positive control spots on the EMAPII treated and untreated 
Figure 20: Cytokine protein profile of JAWSII cells after EMAPII 
treatment 
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blots. The pixel densities of individual cytokines on EMAPII treated blots were 
divided by the pixel densities of the control spots. The results are reported as 
percentage of control.    
 
Cell Surface Marker Expression 
In order to activate T cells, the antigens have to be presented in the context of  
MHCI or MHCII molecules by an antigen presenting cell along with additional co-
stimulatory signals through CD80 and CD86 (104). Abrogating the ability of DC to 
activate T cells will clearly give tumor cells an added advantage since they can evade T 
cell mediated anti-tumor responses. To ascertain whether EMAPII can down regulate 
MHC expression by dendritic cells, BMDC were incubated in the presence or absence of 
EMAPII for 48 hours. Cells were incubated with FITC conjugated anti-mouse I-A or 
anti-mouse CD86 antibody and PE conjugated anti-mouse CD80 antibody. Cells were 
double stained for CD80 and I-A. After 30 minutes incubation on ice and after washing, 
the cells were resuspended in PBS-Sodium azide-BGS solution and analyzed by flow 
cytometry for MHCII/Ia [murine counterpart], CD80 and CD86 expression. EMAPII did 
not up regulate or down regulate IA/ CD80 or CD86 expression on JAWSII or BMDC. 
The expression levels of these surface molecules were comparable to that of the untreated 
control (Figures 21-24).  EMAPII did not up regulate the cell surface maker expression 
on dendritic cells implying that it cannot bring about DC maturation like its precursor 
protein pro-EMAPII. However, EMAPII did not down regulate the expression of cell 
surface molecules either thereby suggesting that it does not block DC maturation by 
blocking the signaling through costimulatory molecules and/or  MHCII molecules. 
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Figure 21: The cell surface expression of Ia and CD80 on untreated 
BMDC 
Figure 22: The cell surface expression of CD86 on untreated BMDC 
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Figure 23: The Cell surface expression of CD86 on BMDC treated with 
EMAPII 
Figure 24: The cell surface expression of Ia and CD80 on BMDC 
treated with EMAPII 
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BMDC (1.2x106 /ml) were incubated with EMAPII for 48 hours and the 
expression of IA, CD80 and CD86 were analyzed by flow cytometry using 
FITC or PE conjugated antibodies against IA, CD80 or CD86.  In figure 
23 and 24, the fluorescence intensity on the X axis corresponds to the 
CD86 expression. In figure 21 and 22, the number of IA positive cells (X 
axis) is depicted on the lower right quadrant and the CD80 positive 
cells(Y axis) are on the upper left quadrant. The double positive cells are 
in the upper right quadrant. The cell surface expression was based on 
fluorescence intensity. 
         
Stat3 Expression 
It has been documented that STAT3 can suppress the activation /maturation of 
dendritic cells (81, 105). Tumors elaborate factors that induce hyperactivation of 
JAK2/STAT3 pathway that leads to abnormal DC differentiation. We wanted to 
investigate whether EMAPII is one of the factors released by tumor cells to block the 
differentiation or activation of DC by activating the JAK2/STAT3 pathway. JAWSII cells 
were incubated in the presence of EMAPII or LPS for four hours and the level of 
activated STAT3 protein was assessed by Western Blot. STAT3 is a transcription 
activator that affects dendritic cell functions (78, 81, 105). STAT3 is activated by 
phosphorylation of its tyrosine or serine residues. As shown in figure 25, the levels of 
phosphorylated STAT3 in EMAPII treated DC was comparable to the untreated DC 
control cells. LPS treatment completely failed to activate STAT3. The level of 
phosphorylated STAT3 was quite low in all treated and untreated DC when compared to 
the HeLa cell lysate that was used as a positive control. These results suggest that 
EMAPII does not employ and activate STAT3 and EMAPII is not the tumor derived 
factor that causes an up regulation of STAT3 activation in tumor bearing animals.  
 Lane 1 LPS treated JAWSII cell lysate (replicate 1)
Lane 2 EMAPII
Lane 3 Untreated JAWSII cell lysate (replicate 1 )
Lane 4 LPS treated JAWSII cell lysate (replicate 2)
Lane 5 EMAPII treated JAWSII cell lysate (replicate 2)
Lane 6 Untreated JAWSII cell lysate (replicate 2)
Lane 7
Lane 8 Kaleidoscope Precision Plus Marker 
 
 
 
 
 
 
 
 
 
 
Panel a: JAWSII cells 
GM-CSF starvation, for four hours. The cells were lysed using an RIPA 
based lysis buffer with anti
determined using Bradford assay and equal amounts of protein was 
loaded and run on a reducing PAGE gel. The separated protei
blotted on nitrocellulose sheets and equal loading was ascertained by 
amido black staining. STAT3 phosphorylation was detected by using anti
mouse STAT3 phospho Y705 antibody and t
chemiluminescent substrate.
three independ
Panel b: Total protein stain using amido black to ascertain equal loading. 
 
Discussion 
Cancers represent a heterogeneous multicellular complex of cells and soluble 
factors that interact dynamically to favor uncontrolled proliferation and differentiation. 
This complex interaction involves many players including the tumor cells themselves, 
soluble factors and mediators released by different cell types that represent the 
Figure 
Western Blot
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microenvironment, for e.g., fibroblasts, endothelial cells, and the cells of the acquired and 
innate immune response.  In order to survive and proliferate, tumor cells elaborate 
myriads of factors that could alter the immune system cells. An important immune 
system cell that plays a vital role in anti-tumor immunity is dendritic cells (29-30, 32, 
106). It has been reported that DC from tumor bearing animals or tumor infiltrating DC 
are functionally compromised (107). There are numerous ways in which tumors can 
incapacitate dendritic cells. One of the strategies employed by tumor cells to keep 
immune system cells under check is via induction of apoptosis. Tumor cells release 
factors like EMAPII which can bring about lymphocyte apoptosis (55, 60). Therefore, we 
analyzed the ability of EMAPII to affect the viability of dendritic cells in vitro. We 
demonstrated that Meth A supernatant does not interfere with DC viability and this 
observation is in conjunction with the findings that most tumors are infiltrated with 
dendritic cells suggesting a possible role of these DC in aiding tumor survival (108). This 
observation is in line with the fact that DC orchestrates myriads of immune reactions and 
are important in eliciting regulatory T cell functions and therefore might not be subjected 
to apoptosis by tumor cells that can gain advantage by exploiting the tolerogenic 
functions of DC (109). At this point it can be safely concluded that the tumor takes 
advantage of the chemotactic properties of EMAPII rather than the apoptotic properties 
with respect to dendritic cells.  
 Dendritic cells are professional antigen presenting cells that coordinate many 
immune system functions including activation of T cells. Being antigen presenting cells 
they are equipped with a variety of antigen acquiring mechanisms namely receptor 
mediated endocytosis, macropinocytosis, micropinocytosis and phagocytosis (1). We 
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wanted to determine whether EMAPII could alter the pinocytic abilities of dendritic cells. 
Recombinant EMAPII failed to affect the pinocytic abilities of dendritic cells; however 
MethA tumor supernatant treatment greatly reduced the pinocytic index of dendritic cells 
suggesting a possibility of factors other than EMAPII playing a role in DC pinocytic 
functions. One possible factor could be tumor-derived VEGF since blocking tumor 
supernatant with neutralizing anti-VEGF antibody slightly reversed the reduction in 
pinocytosis induced by MethA tumor supernatant [data not shown]. 
 Phagocytosis is an energy dependent , receptor-mediated phenomenon employed 
by antigen presenting cells to engulf particulate antigens or organisms (1). One of the 
mechanisms employed by tumors to render DC inactive is by inhibiting the phagocytosis 
and antigen processing capacity of dendritic cells (108). Here, we formally demonstrated 
that EMAPII treatment reduced the phagocytic index of both bone-marrow derived 
dendritic cells and JAWSII cells. This observation corroborates the finding that dendritic 
cells in a tumor milieu have reduced phagocytic capacities. EMAPII did not completely 
inhibit the phagocytic abilities of dendritic cells; instead we saw a decrease in the 
phagocytic index in terms of the number of cells engulfed. This could be attributed to 
EMAPII decreasing the receptors required for phagocytosis. Phagocytosis of 
Saccharomyces cerevisiae by murine dendritic cells involves Dectin-1 receptor since 
mannose receptor , the other major receptor employed by phagocytic cells to phagocytize 
yeast cells, is absent in murine dendritic cells (110-111). The reduction in phagocytic 
index after EMAPII treatment suggests a possibility that EMAPII down regulates Dectin-
1 receptor expression on DC cell surface. Though the relevance of Dectin-1 down 
regulation in our current model of study is quite vague, the role played by Dectin-1 
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engagement in dendritic cells in converting regulatory T cells to IL17 releasing T cells 
and cytotoxic T cell priming is worth a mention (112-113). In this context, it is 
understandable if the tumor cells down regulate receptors that could switch a regulatory T 
cell to one with proinflammatory functions. 
 Cytokines are soluble molecules that regulate the responses of immune system 
cells and control the outcome of an immune response (114). Being antigen presenting 
cells, dendritic cells are equipped with a wide array of cytokines which they implement in 
order to coordinate an immune response (1). The cytokine profile of an environment 
plays a crucial role in determining whether inflammatory responses or regulatory 
responses would ensue (114). Cytokines can therefore play a very important role in a 
tumor environment. We assessed the cytokine profile of BMDC after EMAPII treatment. 
The genes that showed significant expression changes after EMAPII treatment were all 
down regulated with respect to the non-treated control cells. There was a 7.7 fold down 
regulation of CD40 ligand. However, since EMAPII treatment did up regulate many 
cytokine genes, it can be safely concluded that EMAPII did not cause an absolute shut 
down of all the pathways. These genes did not meet the statistically significant criteria of 
a p value of 0.05 and below and was not considered for further analysis. The reason why 
beta actin could not employed as the house keeping gene was owing to the fact that 
EMAPII up regulated its expression. Therefore, the gene expression changes induced in 
dendritic cells by EMAPII is selective and not as a result of a complete shutdown of the 
signal transduction pathways.  
 CD40 is a transmembrane glycoprotein that was initially thought to be expressed 
on the surface of cells like dendritic cells, B cells, macrophages/monocytes, endothelial 
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cells, platelets, smooth muscle cells and fibroblasts (115-117). The ligand specific for 
CD40, CD154 or CD40L ,is expressed on T lymphocytes, endothelial cells, smooth 
muscle cells and epithelial cells (118-119). CD40-CD154 interaction provides the 
essential co stimulatory signals required for T cell activation (118). In terms of B cells, 
CD40-CD40L interaction promotes antibody production, cytokine release and isotype 
switching (120). This interaction also improves macrophage effector functions and 
maximizes priming and memory formation in CD8 T lymphocytes via dendritic cells 
(115, 118, 121-123). The above mentioned interactions are between CD 40L on T cells 
and CD40 on antigen presenting cells. However, there is increasing evidence that CD40 
ligand is also expressed by dendritic cells and CD 40 is expressed by T lymphocytes 
(122). CD40 expression on T lymphocytes increased in cases of autoimmunity suggesting 
that CD40 on T cells promotes autoimmunity due to re-expression of recombinase 
activating gene (RAG) and T cell receptor rearrangement in CD40+ T cells (124-
125).Johnson et al. demonstrated that CD8 T cells can be activated in a CD4 independent 
manner by employing CD154 expressed by dendritic cells (122). According to a study 
conducted by Wagner et al., CD40 engagement on thymocytes induces RAG-dependent 
Vα expression suggesting a potential autoimmune trigger (125). Having stated the 
importance and functions of dendritic cell CD40L-T cell CD40 interaction, it is not 
surprising for the tumor cells to down regulate the expression of CD40L on dendritic cell 
surface. CD40 L engagement would potentially work against the tumor due to the ability 
of this interaction to induce RAG gene re-expression and induction of autoimmunity. 
This will potentially lead to anti tumor immunity and enhanced immune response against 
the tumor antigens. We have demonstrated that EMAPII treatment down regulates the 
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expression of CD40L on dendritic cells up to seven fold. This provides a strong argument 
favoring EMAPII being released by tumor cells to enhance tumor survival. 
 CXCL9, CXCL11 and CXCL12 belong to the CXC family of chemokines. These 
chemokines are potent chemo attractants for T lymphocytes and play an important role in 
adaptive immunity. CXCL9 and CXCL11 act via the CXCR3 receptor on T lymphocytes 
whereas CXCL12 utilizes CXCR4 and CXCR7 receptors (126-130). Treatment with 
EMAPII down regulated the expression of these chemokines suggesting that tumor cells 
are trying to keep the adaptive immune responses in check by reducing the infiltration of 
T lymphocytes. Hou et al. demonstrated that EMAPII employs CXCR3 receptors for the 
chemotaxis of endothelial progenitor cells (67). One of the possible explanation to the 
observed decrease in the expression in CXCL9 and CXCL11 could be attributed to the 
fact the release of EMAPII down regulated  the chemokines specific for CXCR3 in order 
to prevent competitive binding. This data strongly favors EMAPII being released in order 
to benefit tumor survival rather than to facilitate anti tumor immunity.  
CCR10 serves as the receptor for CC family of chemokines like CCL27 and CCL28 
(131-132) . CCR10 is usually up regulated in skin homing T lymphocytes and CCL27-
CCR10 interaction mediate this chemotactic response (133) . The role played by CCR10 
in dendritic cells is not very clear. According to Zou et al. CCR10 is up regulated on 
embryonic stem cell derived dendritic cells in response to LIGHT family of proteins and 
is involved in the migration of dendritic cells (134). However, conflicting observations 
are reported by Homey et al.  who claims that CCR10 is not expressed in  CD34 positive 
progenitor –derived or monocytes derived dendritic cells (133). We have demonstrated 
that EMAPII treatment down regulates CCR10 expression however; the significance of 
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this finding is quite unclear at the moment due to the lack of information regarding 
CCR10 expression on dendritic cells. 
BCL6 is a transcriptional repressor expressed mainly by B cells, dendritic cells 
and macrophages (135-137). BCL6 is constitutively expressed in immature dendritic 
cells, however when the cells mature, BCL6 levels are down regulated to allow a window 
of transcriptional activation (137). It was surprising for EMAPII to down regulate BCL6 
since decrease in BCL6 levels usually is accompanied by a mature phenotype. However, 
while analyzing this data, it has to noted that BCL6 expression patterns in DC changes 
with respect to different stimuli ranging from no effect to transient down regulation or 
complete irreversible down regulation (137).  
Interleukin 5 is a hematopoietic growth factor that is essential for the 
differentiation and growth of eosinophils (138) . IL5 also induces the generation of 
cytotoxic T cells and is actively involved in the proliferation and differentiation of B cells 
(139-140).EMAPII treatment reduced the expression of IL5 and its receptor subunit IL5 α 
in dendritic cells rendering them ineffective in terms of aiding in B cell differentiation 
and T cell generation. 
EMAPII treatment substantially reduced the expression and release of 
inflammatory cytokines like IL1 beta, IL3, IL5, IL7 and IL12. IL1 beta is involved in the 
proliferation and differentiation of CD4 T cells and mediates T cell independent DC 
activation. DC activated in the presence of IL1 beta induces stronger IFN gamma 
responses from T cells and the release of CD40 ligand mediated cytokine release which 
includes IL12 (141). Since CD40L is expressed by non T cells as well, non T cells could 
also contribute to the release of CD40 ligand cytokines in the absence of cytokine 
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signaling from T cells.IL1 beta enhances cytokine release via CD40L pathway in a T cell 
independent form. Some of the cytokines that are released after CD40L engagement are 
IL12 and IL6, both detrimental to the tumor (141).  EMAPII treatment not only reduced 
the expression of IL1 beta, it also decreased the CD40L expression on dendritic cells 
thereby reducing the probability of the alternative pathway being activated in the absence 
of T cell help.  This would eliminate the release of cytokines that would activate T cells 
or dendritic cells thereby steering the immune response towards a strong anti-tumor 
response.    
IL3 is a myeloid growth factor that can greatly enhance the tumor antigen 
acquisition and generation of potent tumor specific T cell response (142-143). Dendritic 
cells treated with EMAPII released lower amounts of IL3 when compared to the 
untreated control cells. This would again favor tumor survival by lowering the signals 
that would enhance the activation of cytolytic T cells.  
 IL7 is yet another proinflammatory cytokine that was down regulated by dendritic 
cells in response to EMAPII. IL7 is a pleiotropic cytokine with very important roles in T 
and B cell development (144). It regulates the proliferation and development of T 
lymphocytes  and augments the effector functions of tumor infiltrating lymphocytes 
(145). Due to its ability to enhance anti tumor immune responses, IL7 has been 
considered as a potential candidate for tumor therapy (146). Considering the fact that IL7 
has been used in tumor therapy, it would be advantageous for the tumor to reduce the 
expression of IL7. In our model, release of EMAPII reduced the expression of IL7 
emphasizing the role played by EMAPII in favor of the tumor.  
 Release of IL12 is one of the most important steps that mark the maturation of 
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dendritic cells. IL12 skews the immune response to a Th1 type and majority of the tumors 
devise mechanisms to down regulate this cytokine due to its potent ability to induce 
strong cytotoxic responses (147-148). Several strategies could be employed for this  and 
one would be the release of cytokines that would switch the cytokine profiles of dendritic 
cells and macrophages (149). EMAPII seems to decrease IL12 production from dendritic 
cells thus enhancing the chances for tumor survival. Even though EMAPII did not induce 
the release of IL10 by itself, it augmented the release of IL10 from dendritic cells in the 
presence of LPS and Meth A supernatant. This suggest that EMAPII could, in the 
presence of other stimuli cause a Th1 to Th2 shift which would be beneficial for the 
tumor cells. 
Some of the other cytokines that were down regulated include MIP-1 alpha and 
eotaxin, both of which are up regulated in mature dendritic cells. In the presence of 
EMAPII, DC failed to up regulate these cytokines that are important for inflammatory 
responses and for attracting lymphocytes and monocytes (150-151). 
Dendritic cells are potent professional antigen presenting cells that activate naïve 
T cells. DC are usually found in an immature state in the tissues where they continually 
scan the environment for potential threats. They are the sentinel cells of the immune 
system. Immature DC are characterized by increased antigen acquiring capacity and 
decreased antigen presenting capacity in terms of reduced expression of co stimulatory 
molecules, adhesion molecules and MHCII molecules. DC mature when they interact 
with DC and present their captured antigens to T cells. DC maturation is marked by up 
regulation of co stimulatory molecules, MHC molecules and adhesion molecules and 
down regulation of antigen acquisition. Presentation of antigen on MHCI or MHCII 
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molecule is crucial for T cell activation. The T cell receptor must bind the peptide-MHC 
complex with high affinity.   CD80 and CD86 are the two of the crucial co stimulatory 
molecules required for DC maturation. They bind to CD28 on T cells (10). This pathway 
is very complicated and complex due to the involvement of multiple ligands and 
receptors. Grossi et al. have demonstrated that in the absence of co stimulatory signals 
through the CD80/CD86-CD28 pathway, T cells cannot get activated, instead they 
become anergic and tolerance is induced (152). This phenomenon is very crucial for 
peripheral tolerance toward self antigens. Tumors can take advantage of this DC 
characteristic. EMAPII did not alter the cell surface expression of Ia (mouse MHCII), CD 
80 and CD 86 on dendritic cell surface. This was quite surprising owing to the fact that 
CD80 and CD86 expression and signaling are enhanced and prolonged through a signal 
from CD40-CD40L interaction and EMAPII down regulated the CD40L expression on 
DC (153).  However, it can be argued that EMAPII decreased the CD40L expression on 
DC and not T cells and there is no evidence to indicate that T cell CD40- DC CD40L 
interaction is required for co stimulatory signals. Our data does not corroborate the 
findings of Kim et al. who demonstrated that AIMP1 (pro EMAPII) induced the 
maturation of BMDC with an up regulation of Ia and co stimulatory molecules CD80 and 
CD86 (58). Partly this discrepancy in findings could be attributed to the fact that we used 
EMAPII in our study and they have used the precursor of EMAPII, pro-EMAPII/p43. 
Structurally EMAPII is 22KD and consists of around 166 amino acids; on the other hand 
proEMAPII is 35KD and is made up of 312 amino acids (56). Even though EMAPII is a 
cleavage product of AIMP1, Kim et al. have interchangeably used the terms EMAPII and 
AIMP1 for the 35KD protein they had used in the assays. The up regulation of 
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proinflammatory cytokines like IL-12 by AIMP1 was not mimicked by EMAPII. This 
strongly argues against the use of EMAPII for anti-tumor therapy since EMAPII favors 
tumor survival in terms of altering DC functions.  
 Aberrant expression or activation of STAT3 is associated with DC dysfunctions 
in many tumors (80, 105). We speculated that since EMAPII employs CXCR3 in 
endothelial cells for signaling events, there is a possibility that it would recruit STAT3 
protein as the transcriptional activator. EMAPII did not alter STAT3 transcript level (data 
not shown) or phosphorylated STAT3 proteins suggesting that EMAPII might be 
employing some other transcription factor other than STAT3 and the alterations of DC 
functions that are manifested after EMAPII treatment is most likely to be independent of 
STAT3 pathway. Therefore, the DC dysfunctions that is observed after EMAPII 
treatment is not due to aberrant STAT3 activation.  
 From the results obtained from our study we have proposed a model discerning 
the role played by EMAPII in a tumor milieu. This is illustrated in figure 26.  Figure 27 
depicts the model for effects of EMAPII as described by Tas et al.(52). We have 
modified this model to incorporate the effect of dendritic cells as well (figure 28). When 
tumor cells begin to undergo apoptosis or under hypoxic conditions, pro-EMAPII is 
cleaved in a caspase dependent or independent manner to release EMAPII. The released 
EMAPII attracts dendritic cells from the periphery. We speculate that these DC are 
attracted to the tumor site since the destination of the DC that disappeared after EMAPII 
treatment is not elucidated. The dendritic cells that home into the tumors will have altered 
functions since the binding of EMAPII reduces their phagocytic functions which render 
them ineffective in terms of acquiring tumor associated antigens. This would benefit the 
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tumor since impaired or reduced phagocytosis can render the dendritic cells tolerogenic. 
Complete blocking of phagocytosis however will not work in favor of tumor cells since 
that will abrogate tolerogenic DC from presenting the acquired antigens and thereby 
inducing tolerance towards tumor antigens. EMAPII binding does not result in dendritic 
cell maturation therefore will not up regulate the expression of Ia and co stimulatory 
molecules. Since chemokines like CXCL9,CXCL11 that are released by dendritic cells to 
attract T cells is down regulated in the presence of EMAPII, the number of T cells 
migrating to the tumor milieu will be limited. T cells that manage to migrate to the tumor 
will have a high probability of becoming tolerogenic since autoantigens usually fail to 
induce maturation of DC which in turn will render the T cells anergic. To overcome 
suppressive or tolerogenic signals, T cells must receive signals from CD40 ligand 
interactions and signals from co stimulatory molecules. Though EMAPII does not down 
regulate co stimulatory molecules, it down regulated CD40L expression on DC indicating 
that the signals required for strong inflammatory responses was down regulated. Under 
normal conditions, EMAPII might be released by cells undergoing apoptosis to attract 
dendritic cells in order to induce peripheral tolerance. Tumors are exploiting this function 
of EMAPII to induce peripheral tolerance to benefit their survival. 
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Figure 26: Role of EMAPII in a tumor milieu 
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Figure 27: 
Modified 
model of 
the 
functions 
of EMAPII 
Figure 28: Model depicting EMAPII functions by Tas et al 
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Considering the possible role played by EMAPII in peripheral tolerance, it can be 
used in treating autoimmunity. In conclusion, EMAPII is a multifunctional cytokine 
whose functions are exploited by tumors to benefit their survival. Our study does not 
support the use of this cytokine in treating tumor rather EMAPII has greater potential in 
being used as a therapy for auto immune diseases where in the signals required for 
mounting an auto immune response is hampered. Much work needs to be done to 
elucidate the potential of this cytokine in treating autoimmune disorders. 
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APPENDICES 
 
Appendix 1: Media Composition and Reagents 
Complete JAWSII Growth Medium 
 
 
 
 
 
 
 
SDS PAGE 
5% Stacking Gel 
For 5ml Solution Volume in mls 
29:1 Acrylamide/Bisacrylamide solution 0.83 
1M Tris pH 6.8 0.62 
20% Sodium Dodecyl Sulfate 0.025 
Distilled water 2.9 
Mix and degas for 10 minutes. Just before pouring the gel add 
20% Ammonium persulfate 0.025-0.05 
TEMED 0.05-0.01 
 
10% Resolving Gel 
For 15ml Solution Volume in mls 
29:1 Acrylamide/Bisacrylamide solution 5 
1M Tris pH 8.8 5.6 
20% Sodium Dodecyl Sulfate 0.075 
Distilled water 4.3 
Mix and degas for 10 minutes. Just before pouring the gel add 
20% Ammonium persulfate 0.05 
TEMED 10 
5X Running Buffer  
Glycine 72g 
Trizma Base 15g 
Sodium Dodecyl Sulfate 5g 
Add distilled water to one liter 
 
5X Gel Loading Buffer 
 Volume in mls 
20% SDS 2.5 
1M Tris pH 6.8 1.0 
Distilled water 1.5 
Components  
RPMI 1640  
Fetal Bovine Serum/Bovine Growth Serum 5% 
Penicillin 0.002 µg/ml 
Streptomycin 0.2U/ml 
Glutamine 2mM 
Granulocyte-Macrophage Colony Stimulating factor(GM-CSF) 5-10 ng 
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Glycerol 5 
Bromophenol Blue Few grains 
Beta Mercaptoethanol (just before use) 50µl/ml 
 
Western Blot 
RIPA Lysis Buffer with protease and phosphatase inhibitors 
NaCl 150mM 
Triton X-100 1% 
Sodium desoxycholate 0.5% 
SDS 0.1% 
Tris pH 8 50mM 
Sodium meta vanadate 
Prepared stock solution of 100mM. Set the pH to 9.0, boiled and cooled repeatedly 
until pH stabilized at 9 and the solution turned colorless. 
1mM 
Sodium Azide 0.01% 
PMSF (dissolved in isopropanol) 200µM 
Aminocaproic acid 12.5mM 
Benzaminidine 12.5mM 
 
Transfer Buffer(pH 8.5) 
Tris Base 25mM 
Glycine 0.2M 
Methanol 20% 
Blocking Buffer 
Tween 20 0.1% 
Bovine Serum Albumin 5% w/v 
1X Tris Buffered Saline  
Wash Buffer 
1X Tris Buffered Saline  
Tween 20 0.1% 
 
Destaining Solution 
Glacial Acetic Acid 10% 
Methanol 10% 
 Appendix 2: Pinocytosis
 
 
1. Standard Curve Neutral Red versus Transmittance at 533nm.
 
 
2. Formula for µg neutral red/ 10
Concentration of neutral red/ml = 
µg neutral red/ 106
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6 cells 
µg neutral red obtained from the graph/5
 cells = 106 x concentration of neutral red/ml  
total number of cells used
y = -1.1799x + 82.591
R² = 0.9835
10 20 30 40
Neutral Red Concentration [Microgram]
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Findings and Conclusions:   
Endothelial Monocyte Activating Polypeptide (EMAPII) is chemotactic for 
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EMAPII provides it with a potential to treat auto immune disorders. However, the 
ability of EMAPII to induce tolerance could be exploited by tumor cells. 
Induction of tolerance to self antigens would render tumor cells unsusceptible to 
immune clearance. From our data we conclude that EMAPII favors tumor 
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